<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd">
<html xmlns="http://www.w3.org/1999/xhtml">
<head>

    <title>Pocket Medicine: The Massachusetts General Hospital Handbook of Internal Medicine</title>
    <meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>
  <link rel="stylesheet" type="text/css" href="../stylesheet.css"/>
<link rel="stylesheet" type="text/css" href="../page_styles.css"/>

  


<link href="../calibreHtmlOutBasicCss.css" type="text/css" rel="stylesheet" />

</head>
<body>

<div class="calibreMeta">
  <div class="calibreMetaTitle">
  
  
    
    <h1>
      <a href="../../k34gmbu8.html">Pocket Medicine
</a>
    </h1>
    
    
  
  </div>
  <div class="calibreMetaAuthor">
    Marc Sabatine

  </div>
</div>

<div class="calibreMain">

  <div class="calibreEbookContent">
    
      <div class="calibreEbNavTop">
        
          <a href="part0008.html" class="calibreAPrev">previous page
</a>
        

        
          <a href="part0010.html" class="calibreANext">next page
</a>
        
      </div>
    

    
<h2 class="ct"><a id="h54" class="calibre7"></a><a id="page_4-1" class="calibre7"></a><a href="part0002.html#rh61" class="calibre7">ACID-BASE DISTURBANCES</a></h2>
<p class="h">G<small class="calibre30">ENERAL</small></p>
<p class="h2a"><b class="calibre4">Definitions</b></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Acidemia</b> → pH &lt;7.36, <b class="calibre4">alkalemia</b> → pH &gt;7.44; pH = 6.10 + log([HCO<sub class="calibre8">3</sub>]/[0.03xPCO<sub class="calibre8">2</sub>])</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Acidosis</b> → process that ↑ [H<sup class="calibre15">+</sup>] or ↓ pH by ↓ HCO<sub class="calibre8">3</sub> or ↑ PaCO<sub class="calibre8">2</sub></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Alkalosis</b> → process that ↓ [H<sup class="calibre15">+</sup>] or ↑ pH by ↑ HCO<sub class="calibre8">3</sub> or ↓ PaCO<sub class="calibre8">2</sub></p>
<p class="bl"><span class="sbl">•</span> Primary disorders: metabolic acidosis or alkalosis, respiratory acidosis or alkalosis</p>
<p class="bl"><span class="sbl">•</span> Compensation</p>
<p class="bl1">Respiratory: hyper/hypoventilation alters P<sub class="calibre8">a</sub>CO<sub class="calibre8">2</sub> to counteract 1° metabolic process</p>
<p class="bl1">Renal: excretion/retention of H<sup class="calibre15">+</sup>/HCO<sub class="calibre8">3</sub><sup class="calibre15">–</sup> to counteract 1° respiratory process</p>
<p class="bl1">Respiratory compensation occurs in mins-hrs; renal compensation takes days</p>
<p class="bl1"><i class="calibre3">Compensation usually never fully corrects pH;</i> if pH normal, consider mixed disorder</p>
<table class="t-topbot1">
<colgroup class="calibre9">
<col class="calibre33"/>
<col class="calibre26"/>
<col class="calibre16"/>
</colgroup>
<tr class="calibre12">
<td class="bg1-b" colspan="3"><p class="tabheadc"><b class="calibre4">Consequences of Severe Acid-Base Disturbances</b> <span class="tfont1">(</span><span class="tfont1"><i class="calibre3">NEJM</i></span> <span class="tfont1">1</span><span class="tfont1">998;338:26 &amp;</span> <span class="tfont1">1</span><span class="tfont1">07)</span></p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Organ System</b></p></td>
<td class="bg0-br"><p class="tab"><b class="calibre4">Acidemia (pH</b> &lt;<b class="calibre4">7.20)</b></p></td>
<td class="bg0-b"><p class="tab"><b class="calibre4">Alkalemia (pH</b> &gt;<b class="calibre4">7.60)</b></p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab">Cardiovascular</p></td>
<td class="bg0-br"><p class="tab">↓ contractility, arteriolar vasodilation</p>
<p class="tab">↓ MAP &amp; CO; ↓ response to catecholamines</p>
<p class="tab">↑ risk of arrhythmias</p></td>
<td class="bg0-b"><p class="tab">Arteriolar vasoconstriction</p>
<p class="tab">↓ coronary blood flow</p>
<p class="tab">↑ risk of arrhythmias</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab">Respiratory</p></td>
<td class="bg0-br"><p class="tab">Hyperventilation, ↓ resp. muscle strength</p></td>
<td class="bg0-b"><p class="tab">Hypoventilation</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab">Metabolic</p></td>
<td class="bg0-br"><p class="tab">↑ K (resp. &gt; metab.), insulin resistance</p></td>
<td class="bg0-b"><p class="tab">↓ K, Ca, Mg, PO<sub class="calibre13">4</sub></p></td>
</tr>
<tr class="calibre12">
<td class="bg0-r"><p class="tab">Neurologic</p></td>
<td class="bg0-r"><p class="tab">Δ MS</p></td>
<td class="bg"><p class="tab">Δ MS, seizures, tetany</p></td>
</tr>
</table>
<p class="h2a"><b class="calibre4">Workup</b> <span class="s">(<i class="calibre3">NEJM</i> 2014;371:1434)</span></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Traditional or physiologic approach</b> (Brønsted-Lowry definition of acids &amp; bases)</p>
<p class="bl1">Determine <b class="calibre4">primary disorder:</b> ✔ pH, P<sub class="calibre8">a</sub>CO<sub class="calibre8">2</sub>, HCO<sub class="calibre8">3</sub></p>
<p class="bl1">Determine if <b class="calibre4">degree of compensation</b> is appropriate</p>
<p class="image1"><img src="../images/00061.jpeg" alt="" class="calibre2"/></p>
<table class="t-topbot1">
<colgroup class="calibre9">
<col class="calibre17"/>
<col class="calibre24"/>
</colgroup>
<tr class="calibre12">
<td class="bg1-b" colspan="2"><p class="tabheadc"><b class="calibre4">Compensation for Acid/Base Disorders</b> <span class="tfont1">(</span><span class="tfont1"><i class="calibre3">NEJM</i></span> <span class="tfont1">20</span><span class="tfont1">1</span><span class="tfont1">4;37</span><span class="tfont1">1</span><span class="tfont1">:</span><span class="tfont1">1</span><span class="tfont1">434)</span></p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Primary Disorder</b></p></td>
<td class="bg0-b"><p class="tab"><b class="calibre4">Expected Compensation</b></p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab">Metabolic acidosis</p></td>
<td class="bg0-b"><p class="tab">↓ P<sub class="calibre13">a</sub>CO<sub class="calibre13">2</sub> = 1.2 × ΔHCO<sub class="calibre13">3</sub></p>
<p class="tab">or P<sub class="calibre13">a</sub>CO<sub class="calibre13">2</sub> = (1.5 × HCO<sub class="calibre13">3</sub>) + 8 ± 2 (Winters’ formula)</p>
<p class="tab">(also, P<sub class="calibre13">a</sub>CO<sub class="calibre13">2</sub> ≈ last 2 digits of pH)</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab">Metabolic alkalosis</p></td>
<td class="bg0-b"><p class="tab">↑ P<sub class="calibre13">a</sub>CO<sub class="calibre13">2</sub> = 0.7 × ΔHCO<sub class="calibre13">3</sub></p>
<p class="tab">or P<sub class="calibre13">a</sub>CO<sub class="calibre13">2</sub> = 0.7 (HCO<sub class="calibre13">3</sub>-24) + 40 ± 2 or HCO<sub class="calibre13">3</sub> + 15</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab">Acute respiratory acidosis</p></td>
<td class="bg0-b"><p class="tab">↑ HCO<sub class="calibre13">3</sub> = 0.1 × ΔP<sub class="calibre13">a</sub>CO<sub class="calibre13">2</sub></p>
<p class="tab">(also, ↓ pH = 0.008 × ΔP<sub class="calibre13">a</sub>CO<sub class="calibre13">2</sub>)</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab">Chronic respiratory acidosis</p></td>
<td class="bg0-b"><p class="tab">↑ HCO<sub class="calibre13">3</sub> = 0.35 × ΔP<sub class="calibre13">a</sub>CO<sub class="calibre13">2</sub></p>
<p class="tab">(also, ↓ pH = 0.003 × ΔP<sub class="calibre13">a</sub>CO<sub class="calibre13">2</sub>)</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab">Acute respiratory alkalosis</p></td>
<td class="bg0-b"><p class="tab">↓ HCO<sub class="calibre13">3</sub> = 0.2 × ΔP<sub class="calibre13">a</sub>CO<sub class="calibre13">2</sub></p>
<p class="tab">(also, ↑ pH = 0.008 × ΔP<sub class="calibre13">a</sub>CO<sub class="calibre13">2</sub>)</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-r"><p class="tab">Chronic respiratory alkalosis</p></td>
<td class="bg"><p class="tab">↓ HCO<sub class="calibre13">3</sub> = 0.4 × ΔP<sub class="calibre13">a</sub>CO<sub class="calibre13">2</sub></p></td>
</tr>
</table>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Alternative approaches</b></p>
<p class="bl1">Base excess/deficit <span class="s1r">(<i class="calibre3">NEJM</i> 2018;378:1419)</span></p>
<p class="bl1">Strong ion difference or “Stewart Method” <span class="s1r">(<i class="calibre3">NEJM</i> 2014;371:1821)</span></p>
<p class="h2a"><b class="calibre4">Mixed disorders</b> (more than one primary disorder at the same time)</p>
<p class="bl"><span class="sbl">•</span> If compensation less or greater than predicted, may be two disorders:</p>
<p class="bl1">P<sub class="calibre8">a</sub>CO<sub class="calibre8">2</sub> too low → concomitant 1° resp. alk.; P<sub class="calibre8">a</sub>CO<sub class="calibre8">2</sub> too high → concomitant 1° resp. acid.</p>
<p class="bl1">HCO<sub class="calibre8">3</sub> too low → concomitant 1° met. acid.; HCO<sub class="calibre8">3</sub> too high → concomitant 1° met. alk.</p>
<p class="bl"><span class="sbl">•</span> Normal pH, <i class="calibre3">but...</i></p>
<p class="bl1">↑ P<sub class="calibre8">a</sub>CO<sub class="calibre8">2</sub> + ↑ HCO<sub class="calibre8">3</sub> → resp. acid. + met. alk.</p>
<p class="bl1">↓ P<sub class="calibre8">a</sub>CO<sub class="calibre8">2</sub> + ↓ HCO<sub class="calibre8">3</sub> → resp. alk. + met. acid.</p>
<p class="bl1">Normal P<sub class="calibre8">a</sub>CO<sub class="calibre8">2</sub> &amp; HCO<sub class="calibre8">3</sub>, <i class="calibre3">but</i> ↑ AG → AG met. acid. + met. alk.</p>
<p class="bl1">Normal P<sub class="calibre8">a</sub>CO<sub class="calibre8">2</sub>, HCO<sub class="calibre8">3</sub>, &amp; AG → no disturbance <i class="calibre3">or</i> non-AG met. acid. + met. alk.</p>
<p class="bl"><span class="sbl">•</span> <i class="calibre3">Cannot</i> have resp. acid. (hypoventilation) and resp. alk. (hyperventilation) simultaneously</p>
<p class="capf"><a id="page_4-2" class="calibre1"></a><b class="calibre4">Figure 4-1</b> Acid-base nomogram</p>
<p class="center"><img src="../images/00062.jpeg" alt="" class="calibre2"/></p>
<p class="fn">(Adapted from Brenner BM, ed., <i class="calibre3">Brenner &amp; Rector’s The Kidney</i>, 8th ed., 2007; Ferri F, ed. <i class="calibre3">Practical Guide to the Care of the Medical Patient</i>, 7th ed., 2007)</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">ABG vs. VBG:</b> concordant for pH (~0.04), HCO<sub class="calibre8">3</sub> (~2 mEq) but <b class="calibre4">not</b> PCO<sub class="calibre8">2</sub> (~8±17 mmHg)</p>
<p class="bl1">VBG can be used to <i class="calibre3">screen</i> for hypercarbia w/ PCO<sub class="calibre8">2</sub> cutoff ≥45 mmHg (100% Se),</p>
<p class="bl1"><b class="calibre4">but</b> may not accurately assess <i class="calibre3">degree</i> of hypercarbia <span class="s1r">(<i class="calibre3">Am J Emerg Med</i> 2012;30:896)</span></p>
<p class="h">M<small class="calibre30">ETABOLIC</small> A<small class="calibre30">CIDOSIS</small></p>
<p class="h2a"><b class="calibre4">Initial workup</b> <span class="s">(<i class="calibre3">NEJM</i> 2014;371:1434)</span></p>
<p class="bl"><span class="sbl">•</span> ✔ <b class="calibre4">anion gap</b> (AG) = Na<sup class="calibre15">+</sup> – (Cl<sup class="calibre15">–</sup> + HCO<sub class="calibre8">3</sub><sup class="calibre15">–</sup>) = unmeasured anions – unmeasured cations</p>
<p class="bl1">if ↑ glc, use measured <i class="calibre3">not</i> corrected Na</p>
<p class="bl1">expected AG is [albumin] × 2.5 (ie, 10 if albumin is 4 g/dL, 7.5 if albumin is 3 g/dL)</p>
<p class="bl1">↑ AG → ↑ unmeasured anions such as organic acids, phosphates, sulfates</p>
<p class="bl1">↓ AG → ↓ alb or ↑ unmeasured cations (Ca, Mg, K, Li, Ig), bromide/iodine toxicity</p>
<p class="bl"><span class="sbl">•</span> If ↑ AG, ✔ <b class="calibre4">delta-delta</b> (Δ/Δ = ΔAG/ΔHCO<sub class="calibre8">3</sub>) to assess if there is an additional metabolic</p>
<p class="bl1">acid-base disturbance; ΔAG = (calculated AG – expected AG), ΔHCO<sub class="calibre8">3</sub> = (24 – HCO<sub class="calibre8">3</sub>)</p>
<p class="bl2">Δ/Δ = 1–2 → pure AG metabolic acidosis</p>
<p class="bl2">Δ/Δ &lt; 1 → AG metabolic acidosis <i class="calibre3">and</i> simultaneous non-AG acidosis</p>
<p class="bl2">Δ/Δ &gt; 2 → AG metabolic acidosis <i class="calibre3">and</i> simultaneous metabolic alkalosis</p>
<p class="bl2">For pure lactic acidosis Δ/Δ 1.6 b/c of slow lacatate clearance</p>
<table class="t-topbot1">
<colgroup class="calibre9">
<col class="calibre33"/>
<col class="calibre34"/>
</colgroup>
<tr class="calibre12">
<td class="bg1-b" colspan="2"><p class="tabheadc"><b class="calibre4">Etiologies of AG Metabolic Acidosis</b></p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Ketoacidosis</b></p></td>
<td class="bg0-b"><p class="tab"><b class="calibre4">Diabetes mellitus</b>, alcoholism, starvation <span class="tfont1">(</span><span class="tfont1"><i class="calibre3">NEJM</i></span> <span class="tfont1">20</span><span class="tfont1">1</span><span class="tfont1">4;372:546)</span></p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br2"><p class="tab"><b class="calibre4">Lactic acidosis</b> <span class="tfont1">(</span><span class="tfont1"><i class="calibre3">NEJM</i></span> <span class="tfont1">20</span><span class="tfont1">1</span><span class="tfont1">4; 37</span><span class="tfont1">1</span><span class="tfont1">:2309)</span></p></td>
<td class="bg0-b"><p class="tab"><b class="calibre4">Type A:</b> hypoxic (eg, shock, mesenteric ischemia, CO poisoning, cyanide)</p>
<p class="tabh"><b class="calibre4">Type B:</b> nonhypoxic. ↓ clearance (eg, hepatic dysfxn) or ↑ generation [eg, malig, EtOH, thiamine def., meds (metformin, NRTIs, salicylates, propylene glycol, propofol, isoniazid, linezolid)]</p>
<p class="tabh"><b class="calibre4"><small class="tfont">D</small>-lactic acidosis:</b> short bowel syndrome → precip by glc ingest → metab by colonic bacteria to <small class="tfont">D</small>-lactate; not detected by standard lactate assay</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Renal failure</b></p></td>
<td class="bg0-b"><p class="tab">Accumulation of organic anions (eg, phosphates, sulfates, etc.)</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-r1"><p class="tab"><b class="calibre4">Ingestions</b></p></td>
<td class="bg"><p class="tab"><b class="calibre4">Glycols:</b> <i class="calibre3">Ethylene</i> (antifreeze) → metab to glycolic and oxalic acids</p>
<p class="tabh1"><i class="calibre3">Propylene</i> (pharmaceutical solvent, eg, IV diazepam, lorazepam, and phenobarbital; antifreeze) → lactic acidosis</p>
<p class="tabh1"><i class="calibre3">Diethylene</i> (brake fluid) → diglycolic acid</p>
<p class="tabh"><b class="calibre4">5-oxoproline</b> (pyraglutamic acid): acetaminophen → ↑ organic acid 5- oxoproline in susceptible Pts (malnourished, female, renal failure)</p>
<p class="tab"><b class="calibre4">Methanol</b> (windshield fluid, antifreeze, solvents, fuel): metab to formic acid</p>
<p class="tabh"><b class="calibre4">Aspirin</b>: early resp alkalosis (CNS stim) + late metab acidosis (impairs oxidative phosphorylation → inorganic acids (eg, ketones, lactate)</p></td>
</tr>
</table>
<p class="tsr">“GOLD MARK” = Glycols, Oxoproline, Lactic, D-Lactic, Methanol, ASA, Renal, Ketoacidosis</p>
<p class="h2a"><a id="page_4-3" class="calibre1"></a><b class="calibre4">Workup for AG metabolic acidosis</b></p>
<p class="bl"><span class="sbl">•</span> ✔ for <b class="calibre4">ketonuria</b> (dipstick acetoacetate) or plasma β-hydroxybutyrate (βOHB)</p>
<p class="bl1">nb, urine acetoacetate often not present in early ketoacidosis due to shunting to βOHB; ∴ acetoacetate may later turn ⊕ but does not signify worsening disease</p>
<p class="bl"><span class="sbl">•</span> If ⊖ ketones, ✔ <b class="calibre4">renal function</b>, <b class="calibre4">lactate</b>, <b class="calibre4">toxin screen</b>, and <b class="calibre4">osmolal gap</b></p>
<p class="bl"><span class="sbl">•</span> If obtunded or ↑↑ AG, check <b class="calibre4">osmolal gap</b> (OG) = measured osmoles – calculated osmoles</p>
<p class="bl1">calculated osmoles = (2 × Na) + (glucose/18) + (BUN/2.8) (+ [EtOH/4.6] if have EtOH level and want to test if other ingestions)</p>
<p class="bl1">OG &gt;10 → suggests ingestion (see below) but lacks specificity (can be elevated in lactic acidosis, DKA, and alcoholic ketoacidosis)</p>
<p class="bl1">high-dose lorazepam (&gt;10 mg/h) a/w propylene glycol intoxication</p>
<p class="bl1">OG &amp; AG vary based on timing, initially OG ↑, then ↓ w/ metabolism as AG ↑</p>
<p class="image1"><img src="../images/00063.jpeg" alt="" class="calibre2"/></p>
<table class="t-topbot1">
<colgroup class="calibre9">
<col class="calibre29"/>
<col class="calibre44"/>
</colgroup>
<tr class="calibre12">
<td class="bg1-b" colspan="2"><p class="tabheadc"><b class="calibre4">Etiologies of Non-AG Metabolic Acidosis</b></p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">GI losses of HCO<sub class="calibre13">3</sub></b></p></td>
<td class="bg0-b"><p class="tab">Diarrhea, intestinal or pancreatic fistulas or drainage</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">RTAs</b></p></td>
<td class="bg0-b"><p class="tab"><i class="calibre3">See section on renal tubular acidoses below</i></p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Early renal failure</b></p></td>
<td class="bg0-b"><p class="tab">Impaired generation of ammonia</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Ingestions</b></p></td>
<td class="bg0-b"><p class="tab">Acetazolamide, sevelamer, cholestyramine, toluene</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Dilutional</b></p></td>
<td class="bg0-b"><p class="tab">Due to rapid infusion of bicarbonate-free IV fluids</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Posthypocapnia</b></p></td>
<td class="bg0-b"><p class="tab">Respiratory alkalosis → renal wasting of HCO<sub class="calibre13">3</sub>; rapid correction of resp. alk. → transient acidosis until HCO<sub class="calibre13">3</sub> regenerated</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-r"><p class="tab"><b class="calibre4">Ureteral diversion</b></p></td>
<td class="bg"><p class="tab">Colonic Cl<sup class="calibre35">–</sup>/HCO<sub class="calibre13">3</sub><sup class="calibre35">–</sup> exchange, ammonium reabsorption</p></td>
</tr>
</table>
<p class="h2a"><b class="calibre4">Workup for non-AG metabolic acidosis</b></p>
<p class="bl"><span class="sbl">•</span> Evaluate history for causes (see above)</p>
<p class="bl"><span class="sbl">•</span> ✔ <b class="calibre4">urine anion gap</b> (UAG) = (U<sub class="calibre8">Na</sub> + U<sub class="calibre8">K</sub>) – U<sub class="calibre8">Cl</sub></p>
<p class="bl1">UAG = unmeasured anions – unmeasured cations; NH<sub class="calibre8">4</sub><sup class="calibre15">+</sup> is primary unmeasured cation (represented by U<sub class="calibre8">Cl</sub>). UAG is indirect assay for renal H<sup class="calibre15">+</sup> excretion.</p>
<p class="bl"><span class="sbl">•</span> ⊖ UAG → ↑ renal NH<sub class="calibre8">4</sub><sup class="calibre15">+</sup> excretion → appropriate renal response to acidemia</p>
<p class="bl1">Ddx: GI causes (diarrhea, fistulas, ureteral diversion), IV NS, proximal RTA, ingestions</p>
<p class="bl"><span class="sbl">•</span> ⊕ UAG → failure of kidneys to generate NH<sub class="calibre8">4</sub><sup class="calibre15">+</sup></p>
<p class="bl1">Ddx: distal (type 1, usually ↓ K) or hypoaldo (type IV, usually ↑ K) RTA, early renal failure</p>
<p class="bl"><span class="sbl">•</span> UAG unreliable in polyuria, Na depletion (U<sub class="calibre8">Na</sub> &lt;20), U<sub class="calibre8">pH</sub> &gt;6.5 &amp; HAGMA (causes ⊕ UAG b/c excretion of organic anions). Then use U<sub class="calibre8">Osm</sub> gap = measured U<sub class="calibre8">Osm</sub> – [2×(Na<sup class="calibre15">+</sup> + K<sup class="calibre15">+</sup>) + BUN + glc (mmol/L)]. U<sub class="calibre8">Osm</sub> gap &lt;40 mmol/L indicates impaired NH<sub class="calibre8">4</sub><sup class="calibre15">+</sup> excretion.</p>
<p class="h2a"><b class="calibre4">Renal tubular acidoses (RTAs)</b> <span class="s">(<i class="calibre3">Int J Clin Pract</i> 2011;65:350)</span></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Proximal</b> (Type II): ↓ proximal reabsorption of HCO<sub class="calibre8">3</sub></p>
<p class="bl1">1° (Fanconi’s syndrome) = ↓ proximal reabsorption of HCO<sub class="calibre8">3</sub>, PO<sub class="calibre8">4</sub>, glc, amino acids</p>
<p class="bl1">Acquired: paraprotein (MM, amyloidosis), metals (Pb, Cd, Hg, Cu), ↓ vit D, PNH, renal Tx</p>
<p class="bl1">Meds: acetazolamide, aminoglycosides, ifosfamide, cisplatin, topiramate, tenofovir</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Distal</b> (Type I): defective distal H<sup class="calibre15">+</sup> secretion</p>
<p class="bl1">1°, autoimmune (Sjögren’s, RA, SLE), hypercalciuria, meds (ampho, Li, ifosfamide); normally a/w ↓ K; if with ↑ K → sickle cell, obstruction, renal transplant</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Hypoaldo</b> (Type IV): hypoaldo → ↑ K → ↓ NH<sub class="calibre8">3</sub> synthesis → ↓ urine acid-carrying capacity</p>
<p class="bl1">↓ renin: diabetic nephropathy, NSAIDs, chronic interstitial nephritis, calcineurin inh, HIV</p>
<p class="bl1">↓ aldo production: 1° AI, ACEI/ARBs, heparin, severe illness, inherited (↓ 21-hydroxylase)</p>
<p class="bl1">↓ response to aldosterone</p>
<p class="bl4">meds: K-sparing diuretics, TMP-SMX, pentamidine, calcineurin inhibitors</p>
<p class="bl4">tubulointerstitial disease: sickle cell, SLE, amyloid, DM</p>
<p class="bl"><span class="sbl">•</span> Combined (Type III): rarely discussed or clinically relevant, also called juvenile RTA, has distal &amp; proximal features, can be due to carbonic anhydrase II deficiency</p>
<p class="imagef"><a id="page_4-4" class="calibre1"></a><img src="../images/00064.jpeg" alt="" class="calibre2"/></p>
<p class="fn1"><sup class="calibre35">a</sup><span class="tfont1">Urine pH will rise above 5.3 in the setting of HCO</span><sub class="calibre13">3</sub> <span class="tfont1">load</span></p>
<p class="fn1"><sup class="calibre35">b</sup><span class="tfont1">Fe</span><sub class="calibre13">HCO3</sub> <span class="tfont1">should be checked after an HCO</span><sub class="calibre13">3</sub> <span class="tfont1">load</span></p>
<p class="fn"><sup class="calibre35">c</sup><span class="tfont1">See above for causes of distal RTA (Type I) associated with hyperkalemia</span></p>
<p class="capf"><b class="calibre4">Figure 4-2</b> Approach to metabolic acidosis</p>
<p class="image"><img src="../images/00065.jpeg" alt="" class="calibre2"/></p>
<p class="h2a"><b class="calibre4">Treatment of severe metabolic acidoses (pH</b> &lt;<b class="calibre4">7.2)</b> <span class="s">(<i class="calibre3">Nat Rev Nephrol</i> 2012;8:589)</span></p>
<p class="bl"><span class="sbl">•</span> DKA: insulin, IVF, K repletion <span class="s">(<i class="calibre3">NEJM</i> 2015;372:546)</span>; AKA: dextrose, IVF, replete K, Mg, PO<sub class="calibre8">4</sub></p>
<p class="bl"><span class="sbl">•</span> Lactic acidosis: treat underlying condition, avoid vasoconstrictors, avoid “Type B” meds</p>
<p class="bl"><span class="sbl">•</span> Renal failure: hemodialysis</p>
<p class="bl"><span class="sbl">•</span> Methanol &amp; ethylene glycol: fomepizole (20 mg/dL), vit. B<sub class="calibre8">1</sub> &amp; B<sub class="calibre8">6</sub> (ethylene glycol), folate (methanol), dialysis (if AKI, VS unstable, vision Δ or &gt;50 mg/dL) <span class="s">(<i class="calibre3">NEJM</i> 2018;378:270)</span></p>
<p class="bl"><span class="sbl">•</span> Alkali therapy: if pH &lt;7.1 or &lt;7.2 and co-existing AKI <span class="s">(<i class="calibre3">Lancet</i> 2018;392:21)</span></p>
<p class="bl"><span class="sbl">•</span> NaHCO<sub class="calibre8">3</sub>: amps by IV push or infusion of three 50-mmol amps in 1 L D<sub class="calibre8">5</sub>W if less urgent</p>
<p class="bl1">can estimate mmol of HCO<sub class="calibre8">3</sub> needed as [desired-current HCO<sub class="calibre8">3</sub>]<sub class="calibre8">serum</sub> × wt (kg) × 0.4</p>
<p class="bl1">side effects: ↑ volume, ↑ Na, ↓ ICa, ↑ P<sub class="calibre8">a</sub>CO<sub class="calibre8">2</sub> (&amp; ∴ intracellular acidosis; ∴ <i class="calibre3">must ensure adequate ventilation</i> to blow off CO<sub class="calibre8">2</sub>)</p>
<p class="h">M<small class="calibre30">ETABOLIC</small> A<small class="calibre30">LKALOSIS</small></p>
<p class="h2a"><b class="calibre4">Pathophysiology</b> <span class="s">(<i class="calibre3">Clin Physio Acid-Base</i> 2001; <i class="calibre3">CJASN</i> 2008;3:1861)</span></p>
<p class="bl"><span class="sbl">•</span> Saline-responsive etiologies require <i class="calibre3">initiating event</i> and <i class="calibre3">maintenance phase</i></p>
<p class="bl"><span class="sbl">•</span> <i class="calibre3">Initiating event:</i> net HCO<sub class="calibre8">3</sub><sup class="calibre15">−</sup> reabsorption (due to loss of volume, Cl<sup class="calibre15">-</sup>, and/or K<sup class="calibre15">+</sup>) or loss of H<sup class="calibre15">+</sup></p>
<p class="bl1"><b class="calibre4">Loss of H+</b> (± Cl<sup class="calibre15">-</sup>) from GI tract, kidneys, or transcellular shift in hypokalemia</p>
<p class="bl1"><b class="calibre4">Contraction alkalosis:</b> loss of HCO<sub class="calibre8">3</sub><sup class="calibre15">-</sup>-poor fluid → extracellular fluid “contracts” around fixed amount of HCO<sub class="calibre8">3</sub><sup class="calibre15">-</sup> → ↑ HCO<sub class="calibre8">3</sub><sup class="calibre15">-</sup> concentration</p>
<p class="bl1"><b class="calibre4">Exogenous alkali:</b> iatrogenic HCO<sub class="calibre8">3</sub><sup class="calibre15">-</sup> (with renal impairment), milk-alkali syndrome</p>
<p class="bl1"><b class="calibre4">Posthypercapnia:</b> resp. acidosis → compensation with H<sup class="calibre15">+</sup> excretion and HCO<sub class="calibre8">3</sub><sup class="calibre15">-</sup> retention; rapid correction of hypercapnia (eg, intubation) → transient excess HCO<sub class="calibre8">3</sub><sup class="calibre15">-</sup></p>
<p class="bl"><span class="sbl">•</span> <i class="calibre3">Maintenance phase</i></p>
<p class="bl1"><b class="calibre4">Volume depletion</b> → ↑ ATII → ↑ PCT reabsorption of HCO<sub class="calibre8">3</sub><sup class="calibre15">-</sup> &amp; ↑ aldosterone (see below)</p>
<p class="bl1"><b class="calibre4">Cl</b><sup class="calibre15">-</sup> <b class="calibre4">depletion</b> → ↓ Cl<sup class="calibre15">-</sup> uptake in macula densa → ↑ RAS &amp; ↑ CCD Cl<sup class="calibre15">-</sup>/HCO<sub class="calibre8">3</sub><sup class="calibre15">-</sup> exchanger</p>
<p class="bl1"><b class="calibre4">Hypokalemia</b> → transcellular K<sup class="calibre15">+</sup>/H<sup class="calibre15">+</sup> exchange; intracellular acidosis → HCO<sub class="calibre8">3</sub><sup class="calibre15">-</sup> reabsorption and ammoniagenesis &amp; ↑ distal H<sup class="calibre15">+</sup>-K<sup class="calibre15">+</sup>-ATPase activity → HCO<sub class="calibre8">3</sub><sup class="calibre15">-</sup> retention</p>
<p class="bl1"><b class="calibre4">Hyperaldosteronism</b> (1° or 2°) → ↑ CCD α-intercalated H<sup class="calibre15">+</sup> secretion w/ HCO<sub class="calibre8">3</sub><sup class="calibre15">-</sup> retention &amp; Na<sup class="calibre15">+</sup> reabsorption in principal cell → H<sup class="calibre15">+</sup> secretion (for electrical neutrality)</p>
<table class="t-topbot1">
<colgroup class="calibre9">
<col class="calibre33"/>
<col class="calibre34"/>
</colgroup>
<tr class="calibre12">
<td class="bg1-b" colspan="2"><a id="page_4-5" class="calibre1"></a><p class="tabheadc"><b class="calibre4">Etiologies of Metabolic Alkalosis</b></p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Saline responsive</b></p>
<p class="tab">UCl &lt; 25</p></td>
<td class="bg0-b"><p class="tab"><b class="calibre4">GI loss of H</b><sup class="calibre35">+</sup>: emesis, NGT suction, villous adenoma, chloridorrhea</p>
<p class="tab"><b class="calibre4">Renal loss</b>: loop/thiazide, ↓ Cl intake, milk-alkali, Pendred syndrome</p>
<p class="tab">Posthypercapnia, sweat losses in cystic fibrosis</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-r"><p class="tab"><b class="calibre4">Saline resistant</b></p>
<p class="tab">UCl &gt;40</p></td>
<td class="bg"><p class="tab"><i class="calibre3">Hypertensive</i> <b class="calibre4">(mineralocorticoid excess)</b></p>
<p class="tab1">1° hyperaldosteronism (eg, Conn’s)</p>
<p class="tab1">2° hyperaldosteronism (eg, renovascular dis., renin-secreting tumor)</p>
<p class="tab1">Non-aldo (Cushing’s, Liddle’s, exogenous mineralocorticoids, licorice)</p>
<p class="tab"><i class="calibre3">Normotensive</i></p>
<p class="tab1">Severe hypokalemia (K&lt;2); exogenous alkali load (w/ AKI or ↓ vol)</p>
<p class="tab1">Bartter’s syndrome (loop-like); Gitelman’s syndrome (thiazide-like)</p></td>
</tr>
</table>
<p class="h2a"><b class="calibre4">Workup</b></p>
<p class="bl"><span class="sbl">•</span> Check <b class="calibre4">volume status</b> and <b class="calibre4">U</b><sub class="calibre8"><b class="calibre4">Cl</b></sub></p>
<p class="bl1">U<sub class="calibre8">Cl</sub> &lt;25 mEq/L → saline responsive</p>
<p class="bl1">U<sub class="calibre8">Cl</sub> &gt;40 mEq/L → saline resistant (unless currently receiving diuretics)</p>
<p class="bl1">(U<sub class="calibre8">Na</sub> unreliable determinant of volume status in alkalemia → ↑ HCO<sub class="calibre8">3</sub><sup class="calibre15">-</sup> excretion → ↑ Na excretion; negatively charged HCO<sub class="calibre8">3</sub><sup class="calibre15">-</sup> w/ Na<sup class="calibre15">+</sup> maintaining electrical neutrality)</p>
<p class="bl1">If U<sub class="calibre8">Cl</sub> &gt;40 and volume replete, ✔ U<sub class="calibre8">K</sub>; U<sub class="calibre8">K</sub> &lt; 20 laxative abuse; U<sub class="calibre8">K</sub> &gt;30, ✔ <b class="calibre4">blood pressure</b></p>
<p class="capf"><b class="calibre4">Figure 4-3</b> Approach to metabolic alkalosis</p>
<p class="image"><img src="../images/00066.jpeg" alt="" class="calibre2"/></p>
<p class="h2a"><b class="calibre4">Treatment of severe metabolic alkalosis (pH</b> &gt;<b class="calibre4">7.6)</b> <span class="s">(<i class="calibre3">JASN</i> 2012;23:204)</span></p>
<p class="bl"><span class="sbl">•</span> If saline responsive: resuscitate with Cl-rich solution (NS), replete K, d/c diuretics cardiopulmonary disease precludes hydration, can use KCl, acetazolamide, HCl</p>
<p class="bl"><span class="sbl">•</span> If NGT drainage that cannot be stopped: PPI or H<sub class="calibre8">2</sub>-blocker <span class="s">(<i class="calibre3">Clin Nephro</i> 2006;66:391)</span></p>
<p class="bl"><span class="sbl">•</span> Hyperaldosteronism: treat underlying condition, K-sparing diuretic, resect adenoma if 1<sup class="calibre15">o</sup></p>
<p class="h">R<small class="calibre30">ESPIRATORY</small> A<small class="calibre30">CIDOSIS</small> <span class="s1">(<i class="calibre22">NEJM</i> 1989;321:1223; <i class="calibre22">Crit Care</i> 2010;14:220)</span></p>
<p class="h2a"><b class="calibre4">Etiologies</b> <span class="s">(also see “Hypercapnia”; PaCO2 = VCO2/VE(1-VD/VT); VE= RR x VT)</span></p>
<p class="bl"><span class="sbl">•</span> ↑ <b class="calibre4">CO<sub class="calibre8">2</sub> production</b> (↑ VCO<sub class="calibre8">2</sub>): fever, thyrotoxicosis, sepsis, steroids, overfeeding (carbs)</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">CNS depression</b> (↓ RR and/or V<sub class="calibre8">T</sub>): sedatives (opiates, benzos, etc.), CNS trauma, central sleep apnea, obesity hypoventilation, hypothyroidism</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Neuromuscular disorders</b> (↓ V<sub class="calibre8">T</sub>)<b class="calibre4">:</b> Guillain-Barré, poliomyelitis, ALS, MS, paralytics, myasthenia gravis, muscular dystrophy, severe ↓ P &amp; K, high spinal cord injury</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Chest wall</b> (↓ V<sub class="calibre8">T</sub>): PTX, hemothorax, flail chest, kyphoscoliosis, ankylosing spondylitis</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Upper airway</b> (↓ V<sub class="calibre8">T</sub>)<b class="calibre4">:</b> foreign body, laryngospasm, OSA, esophageal intubation</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Lower airway (gas exchange)</b> (↑ V<sub class="calibre8">D</sub> and/or ↓ V<sub class="calibre8">T</sub>): asthma, COPD, pulm edema, IPF</p>
<p class="bl1">Often hypoxia → ↑ RR → resp. alk., but muscle fatigue → resp. acid</p>
<p class="bl"><span class="sbl">•</span> Post infusion of bicarbonate in acidemic Pt w/ limited ability to ↑ minute ventilation</p>
<p class="h">R<small class="calibre30">ESPIRATORY</small> A<small class="calibre30">LKALOSIS</small></p>
<p class="h2a"><b class="calibre4">Etiologies</b> <span class="s">(<i class="calibre3">NEJM</i> 2002;347:43; <i class="calibre3">Crit Care</i> 2010;14:220)</span></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Hypoxia</b> → <b class="calibre4">hyperventilation:</b> pneumonia, CHF, PE, restrictive lung disease, anemia</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Primary hyperventilation</b></p>
<p class="bl1">CNS stimulation, pain, anxiety, trauma, stroke, CNS infection, pontine tumors</p>
<p class="bl1">drugs: salicylates toxicity (early), β-agonists, progesterone, methylxanthines, nicotine</p>
<p class="bl1">pregnancy, sepsis, hepatic failure, hyperthyroidism, fever</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Pseudorespiratory alkalosis:</b> ↓ perfusion w/ preserved ventilation (eg, CPR, severe HoTN) → ↓ delivery of CO<sub class="calibre8">2</sub> to lungs for excretion; low P<sub class="calibre8">a</sub>CO<sub class="calibre8">2</sub> but ↑ tissue CO<sub class="calibre8">2</sub></p>
<h2 class="ct"><a id="h55" class="calibre7"></a><a id="page_4-6" class="calibre7"></a><a href="part0002.html#rh62" class="calibre7">SODIUM AND WATER HOMEOSTASIS</a></h2>
<p class="h">O<small class="calibre30">VERVIEW</small></p>
<p class="h2a"><b class="calibre4">General</b> <span class="s">(<i class="calibre3">NEJM</i> 2015;372:55 &amp; 373:1350)</span></p>
<p class="bl"><span class="sbl">•</span> Disorders of serum sodium are generally due to Δs in <i class="calibre3">total body water</i>, not sodium</p>
<p class="bl"><span class="sbl">•</span> Hyper- or hypo-osmolality → rapid water shifts → Δs in brain cell volume → Δ MS, seizures</p>
<p class="h2a"><b class="calibre4">Key hormones</b></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Antidiuretic hormone (ADH):</b> primary hormone that regulates <i class="calibre3">sodium concentration</i></p>
<p class="bl1"><i class="calibre3">Stimuli:</i> hyperosmolality (290–295 mOsm), ↓↓ effective arterial volume, angiotensin II</p>
<p class="bl1"><i class="calibre3">Action:</i> insertion of aquaporin-2 channels in principal cells → passive water reabsorption</p>
<p class="bl1"><b class="calibre4">urine osmolality</b> is an indirect functional assay of the ADH-renal axis</p>
<p class="bl1">U<sub class="calibre8">osm</sub> range: 50 mOsm/L (no ADH) to 1200 mOsm/L (maximal ADH)</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Aldosterone:</b> primary hormone that regulates <i class="calibre3">total body sodium</i> (and ∴ volume)</p>
<p class="bl1"><i class="calibre3">Stimuli for secretion:</i> hypovolemia (via renin and angiotensin II), hyperkalemia</p>
<p class="bl1"><i class="calibre3">Action:</i> iso-osmotic principal cell reabsorption of Na via epithelial Na channel (ENaC) in exchange for K<sup class="calibre15">+</sup> or H<sup class="calibre15">+</sup></p>
<p class="h">H<small class="calibre30">YPONATREMIA</small></p>
<p class="h2a"><b class="calibre4">Pathophysiology</b> <span class="s">(<i class="calibre3">JASN</i> 2008;19:1076; <i class="calibre3">NEJM</i> 2015;372:1349)</span></p>
<p class="bl"><span class="sbl">•</span> Free water clearance (C<sub class="calibre8">H²O</sub>) = solute (intake) excretion/U<sub class="calibre8">osm</sub> normal dietary solute load ~750 mOsm/d, minimum U<sub class="calibre8">osm</sub> = 50 mOsm/L → excrete ~15 L</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Excess H</b><sub class="calibre8"><b class="calibre4">2</b></sub><b class="calibre4">O relative to Na</b>, usually due to ↑ <b class="calibre4">ADH</b></p>
<p class="bl"><span class="sbl">•</span> ↑ ADH may be <i class="calibre3">appropriate</i> (eg, hypovolemia or hypervolemia with ↓ EAV)</p>
<p class="bl"><span class="sbl">•</span> ↑ ADH may be <i class="calibre3">inappropriate</i> (SIADH)</p>
<p class="bl"><span class="sbl">•</span> Rarely, ↓ ADH (appropriately suppressed), but kidneys unable to maintain nl [Na]<sub class="calibre8">serum</sub></p>
<p class="bl1">↑ <i class="calibre3">H<sub class="calibre8">2</sub>O intake (1</i>° <i class="calibre3">polydipsia):</i> ingestion of massive quantities (usually &gt;15 L/d) of free H<sub class="calibre8">2</sub>O overwhelms diluting ability of kidney → H<sub class="calibre8">2</sub>O retention</p>
<p class="bl1">↓ solute intake (“tea &amp; toast” &amp; beer potomania<i class="calibre3">):</i> ↓↓ daily solute load → insufficient solute to excrete H<sub class="calibre8">2</sub>O intake (eg, if only 250 mOsm/d, minimum U<sub class="calibre8">osm</sub> = 50 mOsm/L → excrete in ~5 L; if H<sub class="calibre8">2</sub>O ingestion exceeds this amount → H<sub class="calibre8">2</sub>O retention)</p>
<p class="h2a"><b class="calibre4">Workup</b> <span class="s">(<i class="calibre3">JASN</i> 2012;23:1140 &amp; 2017;28:1340; <i class="calibre3">Crit Care</i> 2013;17:206; <i class="calibre3">NEJM</i> 2015;372:55)</span></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">History:</b> (1) acute vs. chronic (&gt;48 h); (2) sx severity; (3) risk for neuro complications (alcoholism, malnourished, cirrhosis, older females on thiazides, hypoxia, hypoK)</p>
<p class="bl"><span class="sbl">•</span> Measure <b class="calibre4">plasma osmolality</b></p>
<p class="bl1"><i class="calibre3">Hypotonic (P<sub class="calibre8">osm</sub></i> &lt;<i class="calibre3">280)</i> most common scenario; true excess of free H<sub class="calibre8">2</sub>O relative to Na</p>
<p class="bl1"><i class="calibre3">Isotonic (P<sub class="calibre8">osm</sub> 280</i>–<i class="calibre3">295):</i> rare lab artifact from hyperlipidemia or hyperproteinemia</p>
<p class="bl1"><i class="calibre3">Hypertonic (P<sub class="calibre8">osm</sub></i> &gt;<i class="calibre3">295):</i> excess of another effective osmole (eg, glucose, mannitol) that draws H<sub class="calibre8">2</sub>O intravascularly; for each 100 mg/dL ↑ glc &gt;100 mg/dL → ↓ [Na] by ~2 mEq/L</p>
<p class="bl"><span class="sbl">•</span> For hypotonic hyponatremia, ✔ <b class="calibre4">volume status</b> (JVP, skin turgor, dry axilla, mucous membranes, edema, ascites), effusions, vital signs, orthostatics, BUN/Cr, FE<sub class="calibre8">UricAcid</sub>, U<sub class="calibre8">Na</sub></p>
<p class="bl"><span class="sbl">•</span> Measure <b class="calibre4">U</b><sub class="calibre8"><b class="calibre4">osm</b></sub>, although useful for dx in limited circumstances, b/c almost always &gt;300</p>
<p class="bl1">U<sub class="calibre8">osm</sub> &lt;100 in ↑ H<sub class="calibre8">2</sub>O intake (1<sup class="calibre15">o</sup> polydipsia) or ↓ solute intake (beer potomania, “tea &amp; toast”)</p>
<p class="bl1">U<sub class="calibre8">osm</sub> &gt;300 does not mean SIADH; must determine if ↑ ADH appropriate or inappropriate</p>
<p class="bl1">however, U<sub class="calibre8">osm</sub> can be important when deciding on <i class="calibre3">treatment</i> (see below)</p>
<p class="bl"><span class="sbl">•</span> If euvolemic and ↑ U<sub class="calibre8">osm</sub>, evaluate for glucocorticoid insufficiency and hypothyroidism</p>
<p class="bl"><span class="sbl">•</span> If available, consider FE<sub class="calibre8">UricAcid</sub> as &gt;12% suggests SIADH <span class="s">(<i class="calibre3">J Clinc Endo</i> 2008;93:2991)</span></p>
<p class="capf"><b class="calibre4">Figure 4-4</b> Approach to hyponatremia</p>
<p class="image"><img src="../images/00067.jpeg" alt="" class="calibre2"/></p>
<p class="h2a"><a id="page_4-7" class="calibre1"></a><b class="calibre4">Hypovolemic hypotonic hyponatremia</b> <span class="s">(ie, ↓↓ total body Na, ↓ TBW)</span></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Renal losses</b> (U<sub class="calibre8">Na</sub> &gt;20 mEq/L, FE<sub class="calibre8">Na</sub> &gt;1%): diuretics (esp. thiazides, because loop diuretics</p>
<p class="bl1">↓ tonicity of medullary interstitium, Δ for H<sub class="calibre8">2</sub>O absorption, &amp; ∴ urine concentrating ability), salt-wasting nephropathy, cerebral salt wasting, mineralocorticoid deficiency</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Extrarenal losses</b> (U<sub class="calibre8">Na</sub> &lt;10 mEq/L, U<sub class="calibre8">Cl</sub> &lt;10 mEq/L if alkalemia, FE<sub class="calibre8">Na</sub> &lt;1%): hemorrhage, GI loss (diarrhea or vomiting), third-spacing (pancreatitis), ↓ PO intake, insensible losses</p>
<p class="h2a"><b class="calibre4">Euvolemic hypotonic hyponatremia</b> <span class="s">(ie, ↑ TBW relative to total body Na)</span></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">SIADH</b> (euvolemia or mild hypervolemia, typically <b class="calibre4">inapprop U<sub class="calibre8">osm</sub></b> &gt;<b class="calibre4">100,</b> U<sub class="calibre8">Na</sub> &gt;20 mEq/L)</p>
<p class="bl1"><b class="calibre4">Malignancy:</b> lung (SCLC), brain, GI, GU, lymphoma, leukemia, thymoma, mesothelioma</p>
<p class="bl1"><b class="calibre4">Pulmonary:</b> pneumonia, TB, aspergillosis, asthma, COPD, PTX, mechanical ventilation</p>
<p class="bl1"><b class="calibre4">Intracranial:</b> trauma, stroke, SAH, seizure, infxn, hydrocephalus, Guillain-Barré</p>
<p class="bl1"><b class="calibre4">Drugs:</b> antipsychotics, antidepress. (SSRI, TCA, MAOi), haloperidol, chemo (vincristine, cisplatin), AVP, MDMA, NSAIDs, opiates, amiodarone <span class="s1r">(<i class="calibre3">Am J Kidney Dis</i> 2008;52:144)</span></p>
<p class="bl1"><b class="calibre4">Miscellaneous:</b> pain, nausea, postoperative state</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Endocrinopathies:</b> ↑ ADH activity seen in <i class="calibre3">glucocorticoid deficiency</i> (co-secretion of ADH &amp; CRH) and <i class="calibre3">severe hypothyroidism/myxedema coma</i> (↓ CO/SVR → ADH release &amp; ↓ GFR)</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Psychogenic polydipsia</b> (U<sub class="calibre8">osm</sub> &lt;100, ↓ FE<sub class="calibre8">Uric Acid</sub>): usually intake &gt;15 L/d</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Low solute</b> (↓ U<sub class="calibre8">Na</sub>, ↓ U<sub class="calibre8">osm</sub>) “tea &amp; toast”; beer potomania</p>
<p class="bl"><span class="sbl">•</span> Reset osmostat: chronic malnutrition (↓ intracellular osmoles) or pregnancy (hormonal</p>
<p class="bl1">effects) → ADH physiology reset to regulate a lower [Na]<sub class="calibre8">serum</sub></p>
<p class="h2a"><b class="calibre4">Hypervolemic hypotonic hyponatremia</b> <span class="s">(ie, ↑ total body Na, ↑ ↑ TBW)</span></p>
<p class="bl"><span class="sbl">•</span> ↓ EAV → ↑ RAAS → ↑ aldosterone &amp; ↑ adrenergic tone → ↑↑ ADH <span class="s1r">(<i class="calibre3">Am J Med</i> 2013;126:S1)</span></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">CHF</b> (↓ CO &amp; renal venous congestion → ↓ EAV; U<sub class="calibre8">Na</sub> &lt;10 mEq/L, FE<sub class="calibre8">Na</sub> &lt;1%)</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Cirrhosis</b> (splanchnic arterial vasodilation + ascites → ↓ EAV; U<sub class="calibre8">Na</sub> &lt;10 mEq/L, FE<sub class="calibre8">Na</sub> &lt;1%)</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Nephrotic syndrome</b> (hypoalbuminemia → edema → ↓ EAV; U<sub class="calibre8">Na</sub> &lt;10 mEq/L, FE<sub class="calibre8">Na</sub> &lt;1%)</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Advanced renal failure</b> (diminished ability to excrete free H<sub class="calibre8">2</sub>O; U<sub class="calibre8">Na</sub> &gt;20 mEq/L)</p>
<p class="h2a"><b class="calibre4">Treatment</b> <span class="s">(<i class="calibre3">NEJM</i> 2015;372:55; <i class="calibre3">JASN</i> 2017;28:1340; <i class="calibre3">CJASN</i> 2018;13:641 &amp; 984)</span></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Approach:</b> depends on <i class="calibre3">volume status</i>, <i class="calibre3">acuity</i> of hyponatremia, and if <i class="calibre3">symptomatic</i></p>
<p class="bl1">Acute sx: <i class="calibre3">initial</i> rapid correction of [Na]<sub class="calibre8">serum</sub> (2 mEq/L/h for the first 2–3 h) until sx resolve</p>
<p class="bl1">Asx or chronic symptomatic: correct [Na]<sub class="calibre8">serum</sub> at rate of ≤0.5 mEq/L/h</p>
<p class="bl1">Rate ↑ Na <i class="calibre3">should not exceed 6</i> (chronic) to <i class="calibre3">8</i> (acute) mEq/L/d to avoid central pontine myelinolysis/osmotic demyelination (CPM/ODS: paraplegia, dysarthria, dysphagia)</p>
<p class="bl1">If severe (&lt;120) or neuro sx: consider 3% NaCl. dDAVP 1-2 µg q8h in consultation with nephrology (to prevent rapid overcorrection) <span class="s1r">(<i class="calibre3">AJKD</i> 2013;61:571; <i class="calibre3">CJASN</i> 2018; 13:641)</span></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Frequent lab draws</b> and <b class="calibre4">IVF rate adjustments</b> are cornerstones of treatment</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Rapid correction:</b> can lead to CPM/ODS (esp if chronic or Na &lt;120 mEq/L). Should be emergently reversed w/ dDAVP ± D<sub class="calibre8">5</sub>W; partial neuro recovery possible <span class="s1r">(<i class="calibre3">CJASN</i> 2014;9:229)</span>.</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Effect of IV fluids</b> (<a href="http://www.medcalc.com/sodium.html" class="calibre1">http://www.medcalc.com/sodium.html</a>)</p>
<p class="image1"><img src="../images/00068.jpeg" alt="" class="calibre2"/></p>
<p class="imagef"><img src="../images/00069.jpeg" alt="" class="calibre2"/></p>
<p class="fnh"><i class="calibre3">However</i><span class="tfont1">, above assumes infusate retained</span> <i class="calibre3">without output of Na/H<sub class="calibre13">2</sub></i><span class="tfont1">O; adjust for UOP.</span><br class="calibre6"/><span class="tfont1">If Pt euvolemic (eg, SIADH), infused Na will be excreted: for</span> 1 <span class="tfont1">L NS (</span>1<span class="tfont1">54 mEq Na or 308 mOsm solute in</span> 1 <span class="tfont1">L H</span><sub class="calibre13">2</sub><span class="tfont1">O); in SIADH with U</span><sub class="calibre13">osm</sub> = <span class="tfont1">6</span>1<span class="tfont1">6</span> → <span class="tfont1">308 mOsm solute excreted in 0.5 L H</span><sub class="calibre13">2</sub><span class="tfont1">O</span> → <span class="tfont1">net gain 0.5 L H</span><sub class="calibre13">2</sub><span class="tfont1">O</span> → ↓ <span class="tfont1">[Na]</span><sub class="calibre13">serum</sub><span class="tfont1">.</span> ∴ <span class="tfont1">NS</span> <i class="calibre3">worsens</i> <span class="tfont1">Na if U</span><sub class="calibre13">osm</sub> &gt; <span class="tfont1">infusate</span><sub class="calibre13">osm</sub><span class="tfont1">.</span></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Hypovolemic hyponatremia:</b> volume repletion with isotonic 0.9% saline at a <b class="calibre4">slow rate</b>. Once volume replete → stimulus for ADH removed (w/ very short ADH t<sub class="calibre8">½</sub>) → kidneys excrete free H<sub class="calibre8">2</sub>O → serum Na will correct rapidly (D<sub class="calibre8">5</sub>W ± ddAVP if overcorrection)</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">SIADH</b> <span class="s">(<i class="calibre3">NEJM</i> 2007;356:2064; <i class="calibre3">AJKD</i> 2015;65:435)</span>: <b class="calibre4">fluid restrict</b> + treat underlying cause</p>
<p class="bl1"><b class="calibre4">hypertonic saline</b> (± loop diuretic) if sx or Na fails to ↑ w/ fluid restriction 1 L hypertonic saline (3% NaCl) will raise [Na]<sub class="calibre8">serum</sub> by ~10 mEq (see above) ~50 mL/h will ↑ [Na] by ~0.5 mEq/L/h; 100–200 mL/h will ↑ [Na] by ~1–2 mEq/L/h formula only provides estimate; ∴ recheck serum Na frequently (at least q2h)</p>
<p class="bl1">NaCl tabs if chronic and no CHF. Consider urea 0.25-0.5g/kg/d <span class="s1r">(<i class="calibre3">Nephrol Dial Trans</i> 2014;29:ii1)</span></p>
<p class="bl1">aquaresis: vaptans (vasopressin receptor antag) for refractory SIADH <span class="s1r">(<i class="calibre3">NEJM</i> 2015;372:23)</span></p>
<p class="bl1">demeclocycline: causes nephrogenic DI, ↓ U<sub class="calibre8">osm</sub> (rarely used)</p>
<p class="bl"><a id="page_4-8" class="calibre1"></a><span class="sbl">•</span> <b class="calibre4">Hypervolemic hyponatremia:</b> free water restrict (1<sup class="calibre15">st</sup> line), diurese w/ loop diuretics (avoid thiazides) &amp; ↑ EAV (vasodilators to ↑ CO in CHF, colloid infusion in cirrhosis)</p>
<p class="bl1">vaptans sometimes used; however, no mortality benefit, hypoNa recurs after stopping drug, high risk of overcorrection, contraindicated in cirrhosis <span class="s1r">(<i class="calibre3">NEJM</i> 2015;372:2207)</span></p>
<p class="h">H<small class="calibre30">YPERNATREMIA</small></p>
<p class="h2a"><b class="calibre4">Pathophysiology</b> <span class="s">(<i class="calibre3">Crit Care</i> 2013;17:206; <i class="calibre3">NEJM</i> 2015;372:55)</span></p>
<p class="bl"><span class="sbl">•</span> Deficit of water relative to sodium; by definition, all hypernatremic Pts are hypertonic</p>
<p class="bl"><span class="sbl">•</span> Usually <b class="calibre4">loss of hypotonic fluid</b> (ie, “dehydration”); occasionally infusion of hypertonic fluid, post-ATN diuresis w/ loss of low or electrolyte-free water <span class="s">(<i class="calibre3">Am J Neph</i> 2012;36:97)</span></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4"><i class="calibre3">And</i> impaired access to free water</b> (eg, intubation, Δ MS, elderly): hypernatremia is a powerful thirst stimulus, ∴ usually only develops in Pts w/o access to H<sub class="calibre8">2</sub>O or ill</p>
<p class="h2a"><b class="calibre4">Workup</b></p>
<p class="bl"><span class="sbl">•</span> ✔ U<sub class="calibre8">osm</sub>, U<sub class="calibre8">Na</sub>, volume status (vital signs, orthostatics, JVP, skin turgor, BUN, Cr)</p>
<p class="capf"><b class="calibre4">Figure 4-5</b> Approach to hypernatremia</p>
<p class="image"><img src="../images/00070.jpeg" alt="" class="calibre2"/></p>
<p class="h2a"><b class="calibre4">Extrarenal H</b><sub class="calibre8"><b class="calibre4">2</b></sub><b class="calibre4">O loss</b> <span class="s2">(U<sub class="calibre8">osm</sub> &gt;700–800)</span></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">GI H<sub class="calibre8">2</sub>O loss:</b> vomiting, NGT drainage, osmotic diarrhea, fistula, lactulose, malabsorption</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Insensible loss:</b> fever, exercise, ventilation, burns</p>
<p class="h2a"><b class="calibre4">Renal H</b><sub class="calibre8"><b class="calibre4">2</b></sub><b class="calibre4">O loss</b> <span class="s2">(U<sub class="calibre8">osm</sub> &lt;700–800)</span></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Diuresis:</b> osmotic (glucose, mannitol, urea), loop diuretics</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Diabetes insipidus</b> <span class="s">(<i class="calibre3">J Clin Endocrinol Metab</i> 2012;97:3426)</span></p>
<p class="bl1">ADH deficiency (central) or resistance (nephrogenic)</p>
<p class="bl1"><b class="calibre4">Central:</b> hypothalamic or posterior pituitary disease (congenital, trauma/surgery, infiltrative/IgG4); also idiopathic, hypoxic/ischemic encephalopathy (shock, Sheehan’s syndrome), anorexia, sarcoidosis, histiocytosis, drugs: EtOH, phenytoin, snake venom</p>
<p class="bl2">tumors: craniopharyngioma, germinoma, lymphoma, leukemia, meningioma, pituitary</p>
<p class="bl1"><b class="calibre4">Nephrogenic</b> <span class="s1r">(<i class="calibre3">Annals</i> 2006;144:186)</span></p>
<p class="bl2">congenital (ADH receptor V2 mutation, aquaporin-2 mutation; <i class="calibre3">Ped Nephrol</i> 2012;27:2183)</p>
<p class="bl2">drugs: <b class="calibre4">lithium</b>, amphotericin, demeclocycline, foscarnet, cidofovir, ifosfamide</p>
<p class="bl2">metabolic: <b class="calibre4">hypercalcemia</b>, <b class="calibre4">severe hypokalemia</b>, protein malnutrition, congenital</p>
<p class="bl2">tubulointerstitial: <b class="calibre4">postobstruction</b>, <b class="calibre4">recovery phase of ATN</b>, PKD, sickle cell, Sjögren’s, amyloid, pregnancy (placental vasopressinase)</p>
<p class="bl1">DI usually presents as severe polyuria and mild hypernatremia</p>
<p class="h2a"><b class="calibre4">Other</b> <span class="s2">(U<sub class="calibre8">osm</sub> &gt;700–800)</span></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Na overload:</b> hypertonic saline (eg, resuscitation w/ NaHCO<sub class="calibre8">3</sub>), mineralocorticoid excess</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Seizures</b>, ↑ <b class="calibre4">exercise:</b> ↑ intracellular osmoles → H<sub class="calibre8">2</sub>O shifts → transient ↑ [Na]<sub class="calibre8">serum</sub></p>
<p class="h2a"><b class="calibre4">Treatment</b> <span class="s">(<i class="calibre3">NEJM</i> 2015;372:55)</span></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Restore access to H</b><sub class="calibre8"><b class="calibre4">2</b></sub><b class="calibre4">O</b> or supply daily requirement of H<sub class="calibre8">2</sub>O (≥1 L/d)</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Replace free H</b><sub class="calibre8"><b class="calibre4">2</b></sub><b class="calibre4">O deficit</b> (also replace concurrent volume deficit if appropriate):</p>
<p class="image1"><img src="../images/00071.jpeg" alt="" class="calibre2"/></p>
<p class="bl1">eg, 1 L D<sub class="calibre8">5</sub>W given to 70-kg man w/ [Na] = 160 mEq/L will ↓ [Na]<sub class="calibre8">serum</sub> by 3.7 mEq</p>
<p class="bl1">nb, do not forget to correct Na if hyperglycemia also present</p>
<p class="bl"><a id="page_4-9" class="calibre1"></a><span class="sbl">•</span> Rate of correction depends on acuity of onset and risk:</p>
<p class="bl1">chronic (&gt;48 hr): ~12 mEq/d appears safe w/o risk of cerebral edema <span class="s1r">(<i class="calibre3">CJASN</i> 2019;14:656)</span></p>
<p class="bl1">acute (&lt;48 hr): may ↓ Na by 2 mEq/L/h until Na 145</p>
<p class="bl1">hyperacute (min-hrs) &amp; life threatening (ICH, seizure): rapidly infuse D<sub class="calibre8">5</sub>W ± emergent HD</p>
<p class="bl"><span class="sbl">•</span> <i class="calibre3">Estimate:</i> in 70-kg man, 125 mL/h of free H<sub class="calibre8">2</sub>O will ↓ [Na] by ~0.5 mEq/L/h</p>
<p class="bl"><span class="sbl">•</span> ½ NS (77 mEq/L) or ¼ NS (38 mEq/L) provides both volume &amp; free H<sub class="calibre8">2</sub>O (500 or 750 mL of free H<sub class="calibre8">2</sub>O per L, respectively); can give free H<sub class="calibre8">2</sub>O via NGT/OGT</p>
<p class="bl"><span class="sbl">•</span> Formulas provide only estimates; ∴ recheck serum Na frequently</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">DI and osmotic diuresis:</b> see “Polyuria” section below</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Na overload:</b> D<sub class="calibre8">5</sub>W + diuretic. Consider HD if life threatening (ICH, hypertonia, seizures).</p>
<p class="h">P<small class="calibre30">OLYURIA</small></p>
<p class="h2a"><b class="calibre4">Definition and pathophysiology</b></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Polyuria</b> defined as &gt;3 L UOP per day</p>
<p class="bl"><span class="sbl">•</span> Due to an <i class="calibre3">osmotic</i> or a <i class="calibre3">water diuresis;</i> almost always due to osmotic diuresis in inpatients</p>
<p class="h2a"><b class="calibre4">Workup</b></p>
<p class="bl"><span class="sbl">•</span> Perform a timed urine collection (6 h sufficient) and measure U<sub class="calibre8">osm</sub></p>
<p class="bl"><span class="sbl">•</span> 24-h osmole excretion rate = 24-h UOP (actual or estimate) × U<sub class="calibre8">osm</sub></p>
<p class="bl1">&gt;1000 mOsm/d → osmotic diuresis; &lt;800 mOsm/d → water diuresis</p>
<p class="h2a"><b class="calibre4">Osmotic diuresis</b></p>
<p class="bl"><span class="sbl">•</span> Etiologies</p>
<p class="bl1">Hyperglycemia (&gt;180 exceeds PCT reabsorption), mannitol, propylene glycol</p>
<p class="bl1">Na: NaCl IVF, recovering AKI (eg, post obstruction)</p>
<p class="bl1">Urea: ↑ protein feeds, hypercatabolism (burns, steroids), GI bleed, resolving azotemia</p>
<p class="h2a"><b class="calibre4">Water diuresis</b></p>
<p class="bl"><span class="sbl">•</span> Etiologies: <b class="calibre4">diabetes insipidus</b> (DI) (Na<sub class="calibre8">serum</sub> &gt;143) or <b class="calibre4">1</b>° <b class="calibre4">polydipsia</b> (Na<sub class="calibre8">serum</sub> &lt;136)</p>
<p class="bl1">see “Hypernatremia” above for list of causes of central and nephrogenic DI</p>
<p class="bl"><span class="sbl">•</span> Workup of DI: U<sub class="calibre8">osm</sub> &lt;300 (complete) or 300–600 (partial)</p>
<p class="bl1"><b class="calibre4">water deprivation test</b> (start in a.m., ✔ Na<sub class="calibre8">serum</sub>, P<sub class="calibre8">osm</sub>, U<sub class="calibre8">osm</sub>, UOP q1–2h)</p>
<p class="bl1">Deprive until P<sub class="calibre8">osm</sub> &gt;295, then ✔ U<sub class="calibre8">osm</sub>. If U<sub class="calibre8">osm</sub> &lt;300, then administer vasopressin (5 U SC) or dDAVP (10 mg intranasal), then check U<sub class="calibre8">osm</sub> in 1–2 h: U<sub class="calibre8">osm</sub> ↑ by &gt;50% = central DI U<sub class="calibre8">osm</sub> unchanged = nephrogenic DI</p>
<p class="bl1">✔ADH level before and after water deprivation to evaluate proper response</p>
<p class="bl1">Hypertonic saline-stimulated plasma copeptin &gt;4.9 p<sub class="calibre8">moL/L</sub> indicates 1° polydipsia (97% accuracy vs. 77% for water deprivation; <i class="calibre3">NEJM</i> 2018;379:428)</p>
<p class="capf"><b class="calibre4">Figure 4-6</b> Approach to polyuria</p>
<p class="image"><img src="../images/00072.jpeg" alt="" class="calibre2"/></p>
<p class="h2a"><b class="calibre4">Treatment</b></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">1° polydipsia:</b> treat psychiatric illness, check meds, restrict access to free H<sub class="calibre8">2</sub>O</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Osmotic diuresis:</b> address underlying cause, replace free H<sub class="calibre8">2</sub>O deficit (see “Hypernatremia” for formula to calculate) and ongoing losses</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">DI:</b></p>
<p class="bl1">Central DI: desmopressin (dDAVP, 1<sup class="calibre15">st</sup> line), low Na/protein diet + HCTZ, chlorpropamide</p>
<p class="bl1">Nephrogenic DI: treat underlying cause if possible; Na restriction + HCTZ (mild volume depletion → ↓ delivery of filtrate for free H<sub class="calibre8">2</sub>O absorption), consider amiloride for Li-induced DI <span class="s1r">(<i class="calibre3">Kid Int</i> 2009;76:44)</span>, indomethacin <span class="s">(<i class="calibre3">NEJM</i> 1991;324:850)</span> or trial desmopression</p>
<p class="bl1">Pregnancy-induced DI: due to vasopressinase from placenta, ∴ Rx w/ dDAVP</p>
<h2 class="ct"><a id="h56" class="calibre7"></a><a id="page_4-10" class="calibre7"></a><a href="part0002.html#rh63" class="calibre7">POTASSIUM HOMEOSTASIS</a></h2>
<p class="h2a"><b class="calibre4">Overview</b> <span class="s">(<i class="calibre3">NEJM</i> 2015;373:60)</span></p>
<p class="bl"><span class="sbl">•</span> Renal: K excretion regulated at <b class="calibre4">distal nephron</b> (CCD) by principal &amp; α-intercalated cells</p>
<p class="bl1">Distal Na delivery &amp; urine flow: Na absorption → lumen electronegative → K secretion</p>
<p class="bl1">Metabolic alkalemia and aldosterone: increase Na absorption and K secretion</p>
<p class="bl1">nb, diurnal urinary K excretion (day &gt; night), ∴ 24-h sample preferred over spot</p>
<p class="bl"><span class="sbl">•</span> Transcellular shifts: most common cause of acute ∆ in serum K (98% intracellular)</p>
<p class="bl1">Acid-base disturbance: K<sup class="calibre15">+</sup>/H<sup class="calibre15">+</sup> exchange across cell membranes</p>
<p class="bl1">Insulin → stimulates Na-K ATPase → hypokalemia (mitigates postprandial ↑ K)</p>
<p class="bl1">Catecholamines → stimulate Na-K ATPase → hypokalemia; reversed by β-blockers</p>
<p class="bl1">Massive necrosis (eg, tumor lysis, rhabdo, ischemic bowel) → release of intracellular K</p>
<p class="bl1">Hypo- or hyperkalemic periodic paralysis: rare disorders due to channel mutations</p>
<p class="bl"><span class="sbl">•</span> Diet: alone rarely causes ↑ or ↓ K (total body store ~3500 mEq, daily intake ~100 mEq)</p>
<p class="h">H<small class="calibre30">YPOKALEMIA</small></p>
<p class="h2a"><b class="calibre4">Transcellular shifts</b> <span class="s2">(U<sub class="calibre8">K:Cr</sub> &lt;13 mEq/g)</span></p>
<p class="bl"><span class="sbl">•</span> Alkalemia, insulin, catecholamines, β<sub class="calibre8">2</sub>-agonists, hypothermia, hypokalemic/thyrotoxic periodic paralysis, acute ↑ hematopoiesis (megaloblastic anemia Rx w/ B<sub class="calibre8">12</sub>, AML crisis), chloroquine; overdose: Ba/Cs, antipsychotics (risperidone, quetiapine), theophylline</p>
<p class="h2a"><b class="calibre4">GI potassium losses</b> <span class="s2">(U<sub class="calibre8">K:Cr</sub> &lt;13 mEq/g)</span></p>
<p class="bl"><span class="sbl">•</span> GI losses <i class="calibre3">plus</i> metabolic acidosis: diarrhea, laxative abuse, villous adenoma</p>
<p class="bl"><span class="sbl">•</span> Vomiting &amp; NGT drainage usually manifest as <i class="calibre3">renal losses</i> due to 2° hyperaldo &amp; met. alk.</p>
<p class="h2a"><b class="calibre4">Renal potassium losses</b> <span class="s2">(U<sub class="calibre8">K:Cr</sub> &gt;13 mEq/g)</span></p>
<p class="bl"><span class="sbl">•</span> Hypotensive or normotensive</p>
<p class="bl1">acidosis: DKA, RTA [proximal RTA (type II) and some distal RTAs (type I)]</p>
<p class="bl1">alkalosis: diuretics (thiazide &gt; loop), vomiting/NGT drainage (via 2° hyperaldosteronism)</p>
<p class="bl4">Bartter’s syndrome (loop of Henle dysfxn→ furosemide-like effect; <i class="calibre3">JASN</i> 2017;28:2540)</p>
<p class="bl4">Gitelman’s syndrome (DCT dysfxn→ thiazide-like effect <span class="s1r">(<i class="calibre3">KI</i> 2017;91:24)</span></p>
<p class="bl1">drugs: ↑↑ acetaminophen &amp; PCN, gent., amphotericin, foscarnet, cisplatin, ifosfamide</p>
<p class="bl1">↓ Mg: less Mg to inhibit principal cell ROMK channel, ∴ ↑ K secretion <span class="s1r">(<i class="calibre3">JASN</i> 2010;21:2109)</span></p>
<p class="bl"><span class="sbl">•</span> Hypertensive: mineralocorticoid excess</p>
<p class="bl1">1° hyperaldosteronism (eg, Conn’s syndrome, glucocorticoid-remediable aldosteronism)</p>
<p class="bl1">2° hyperaldosteronism (eg, renovascular disease, renin-secreting tumor)</p>
<p class="bl1">Nonaldosterone mineralocorticoid (eg, Cushing’s, Liddle’s [↑ ENaC], exogenous, licorice)</p>
<p class="h2a"><b class="calibre4">Clinical manifestations</b></p>
<p class="bl"><span class="sbl">•</span> Nausea, vomiting, ileus, weakness, muscle cramps, rhabdomyolysis, ↓ insulin secretion</p>
<p class="bl"><span class="sbl">•</span> Renal: ammoniagenesis, phosphaturia, hypocitraturia, NaCl &amp; HCO<sub class="calibre8">3</sub> retention, polyuria</p>
<p class="bl"><span class="sbl">•</span> ECG: may see U waves, ↑ QT, flat Tw, ST depression, ventricular ectopy (PVCs, VT, VF)</p>
<p class="h2a"><b class="calibre4">Workup</b> <span class="s">(<i class="calibre3">Nat Rev Nephrol</i> 2011;7:75)</span></p>
<p class="bl"><span class="sbl">•</span> Identify transcellular shifts &amp; treat. TTKG validity questioned <span class="s">(<i class="calibre3">Curr Op Nephro</i> 2011;20:547)</span>.</p>
<p class="bl"><span class="sbl">•</span> ✔ <b class="calibre4">U</b><sub class="calibre8"><b class="calibre4">K:Cr</b></sub>: &gt;13 mEq/g → renal loss; &lt;13 mEq/g → extrarenal loss <span class="s">(<i class="calibre3">Archives</i> 2004;164:1561)</span></p>
<p class="bl"><span class="sbl">•</span> If renal losses, ✔ <b class="calibre4">BP</b>, <b class="calibre4">acid-base</b>, <b class="calibre4">U<sub class="calibre8">Cl</sub></b> (U<sub class="calibre8">Na</sub> unreliable), U<sub class="calibre8">Ca/Cr</sub>, renin, aldosterone, cortisol</p>
<p class="capf"><b class="calibre4">Figure 4-7</b> Approach to hypokalemia</p>
<p class="image"><img src="../images/00073.jpeg" alt="" class="calibre2"/></p>
<p class="h2a"><a id="page_4-11" class="calibre1"></a><b class="calibre4">Treatment</b> <span class="s">(<i class="calibre3">JAMA</i> 2000;160:2429)</span></p>
<p class="bl"><span class="sbl">•</span> <i class="calibre3">If true potassium deficit:</i> <b class="calibre4">potassium repletion</b> (↓ 1 mEq/L ≈ 200 mEq total body loss)</p>
<p class="bl1">Dosage: 40 mEq PO q4h, 10 mEq/h (IV), 20 mEq/h (central line), 40 mEq in 1L IVF</p>
<p class="bl"><span class="sbl">•</span> Replete K<sup class="calibre15">+</sup> to &gt;3 or &gt;4 mEq/L if high-risk (HTN, CHF, arrhythmias, MI, digoxin, cirrhosis)</p>
<p class="bl"><span class="sbl">•</span> Beware of excessive potassium repletion if transcellular shift cause of hypokalemia</p>
<p class="bl"><span class="sbl">•</span> Treat underlying cause (if ↓ vol: avoid dextrose as ↑ insulin → intracellular potassium shifts)</p>
<p class="bl"><span class="sbl">•</span> Consider Rx that ↓ K loss: ACEI/ARB, K<sup class="calibre15">+</sup>-sparing diuretics, βB</p>
<p class="bl"><span class="sbl">•</span> Replete Mg if &lt;2 mEq/L: IV Mg-SO<sub class="calibre8">4</sub> 1–2 g q2h (oral Mg-oxide poorly tolerated b/c diarrhea)</p>
<p class="bl1">Causes of low Mg: GI loss (diarrhea, bypass, pancreatitis, malnutrition, PPI); renal loss (diuretics, nephrotoxic drugs, EtOH, ↑ Ca, 1° wasting syndromes, volume expansion)</p>
<p class="h">H<small class="calibre30">YPERKALEMIA</small></p>
<p class="h2a"><b class="calibre4">Transcellular shifts</b> <span class="s">(<i class="calibre3">BMJ</i> 2009;339:1019)</span></p>
<p class="bl"><span class="sbl">•</span> Acidemia, ↓ insulin (DM), cell lysis (tumor, rhabdo, ischemic bowel, hemolysis, transfusions, resorbing hematomas, hyperthermia, rewarming), hyperkalemic periodic paralysis, ↑ osmolality. Drugs: succinylcholine, aminocaproic acid, digoxin, β-blockers.</p>
<p class="h2a"><b class="calibre4">Decreased GFR</b></p>
<p class="bl"><span class="sbl">•</span> Any cause of oliguric or anuric AKI or any cause of end-stage renal disease</p>
<p class="h2a"><b class="calibre4">Normal GFR but with</b> ↓ <b class="calibre4">renal K excretion</b></p>
<p class="bl"><span class="sbl">•</span> Normal aldosterone function</p>
<p class="bl1">↓ EAV (K excretion limited by ↓ <b class="calibre4">distal Na delivery &amp; urine flow</b>): CHF, cirrhosis</p>
<p class="bl1">Excessive K intake: in conjunction with impairment in K excretion or transcellular shift</p>
<p class="bl1">Ureterojejunostomy (absorption of urinary K in jejunum)</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Hypoaldosteronism:</b> same as etiologies of hypoaldo RTA (type IV)</p>
<p class="bl1">↓ renin: DM, NSAIDs, chronic interstitial nephritis, HIV, multiple myeloma, Gordon’s</p>
<p class="bl1">Normal renin, ↓ aldo synthesis: 1° adrenal disorders, ACEI, ARBs, heparin, ketoconazole</p>
<p class="bl1">↓ response to aldosterone Meds: K-sparing diuretics, TMP-SMX, pentamidine, calcineurin inhibitors Tubulointerstitial disease: sickle cell, SLE, amyloid, diabetes</p>
<p class="h2a"><b class="calibre4">Clinical manifestations</b></p>
<p class="bl"><span class="sbl">•</span> Weakness, nausea, paresthesias, palpitations; Renal: ↓ NH<sub class="calibre8">4</sub><sup class="calibre15">+</sup> secretion → acidosis</p>
<p class="bl"><span class="sbl">•</span> ECG: ST depression, peaked T waves, ↓ QT, ↑ PR interval, ↑ QRS width, loss of P wave, sine wave pattern, PEA/VF (ECG: low sens., cardiac arrest can be first manifestation!)</p>
<p class="h2a"><b class="calibre4">Workup</b> <span class="s">(<i class="calibre3">Crit Care Med</i> 2008;36:3246)</span></p>
<p class="bl"><span class="sbl">•</span> Rule out pseudohyperkalemia (IVF w/ K, tourniquet, hemolysis, ↑ plt or WBC), rule out transcellular shift</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Assess GFR</b>, if normal, then ✔U<sub class="calibre8">K</sub>, U<sub class="calibre8">Na</sub> (&lt;25 mEq/d ↓ distal Na delivery). ✔ U<sub class="calibre8">K:Cr</sub> (&lt;13 favors ↓ renal K excretion).</p>
<p class="imagef"><img src="../images/00074.jpeg" alt="" class="calibre2"/></p>
<p class="fn1"><sup class="calibre35">a</sup>CaCl contains more calcium and is typically reserved for codes (↑ risk of tissue necrosis) or via central line</p>
<p class="fn"><sup class="calibre35">b</sup>~0.4% intestinal necrosis esp. postop, ileus, SBO/LBO, bowel disease (UC), renal txp <span class="tfont1">(<i class="calibre3">Clin Nephro</i> 2016;85:38)</span></p>
<p class="bl"><span class="sbl">•</span> <i class="calibre3">Rate of onset</i> important to note when establishing a treatment plan</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Stabilize</b> (initial): 10% CaCl (central) or gluconate (IV). ↑ memb. potential → ↓ excitability</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Redistribute</b>: insulin + dextrose (continuous if NPO), HCO<sub class="calibre8">3</sub> <span class="s1r">(<i class="calibre3">KI</i> 1991;41:369)</span>, β<sub class="calibre8">2</sub>-agonists</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Eliminate</b>: SPS (Kayexalate, <i class="calibre3">NEJM</i> 2015;372:211), patiromer (expensive), diuretics (w/ saline if preserved renal fxn), consider emergent HD in life-threatening situations</p>
<p class="bl"><span class="sbl">•</span> Patient information for diet education: <a href="http://www.kidney.org/atoz/content/potassium" class="calibre1">http://www.kidney.org/atoz/content/potassium</a></p>
<h2 class="ct"><a id="h57" class="calibre7"></a><a id="page_4-12" class="calibre7"></a><a href="part0002.html#rh64" class="calibre7">RENAL FAILURE</a></h2>
<p class="h">A<small class="calibre30">CUTE</small> K<small class="calibre30">IDNEY</small> I<small class="calibre30">NJURY</small> (AKI)</p>
<p class="h2a"><b class="calibre4">Definition</b> <span class="s">(<i class="calibre3">KDIGO</i> 2012;2:1)</span></p>
<p class="bl"><span class="sbl">•</span> Stages in ICU correspond to ↑ hospital mortality and LOS <span class="s">(<i class="calibre3">Crit Care Med</i> 2009;37:2552)</span></p>
<p class="bl1">Stage 1: Cr ≥0.3 mg/dL in 2d or ↑ Cr ≥50%, or UOP &lt;0.5 mL/kg/h for ≥6h</p>
<p class="bl1">Stage 2: ↑ Cr 2–3x baseline in 7d or UOP &lt;0.5 mL/kg/h for ≥12h</p>
<p class="bl1">Stage 3: ↑ 3x baseline in 7d, UOP &lt;0.3 mL/kg/h for ≥24h, anuria ≥ 12h, or Cr &gt;4</p>
<p class="bl"><span class="sbl">•</span> <i class="calibre3">Cannot</i> estimate GFR using Cr in setting of AKI or ∆’ing Cr (requires steady state)</p>
<p class="h2a"><b class="calibre4">Workup</b> <span class="s">(<i class="calibre3">NEJM</i> 2014;371:55)</span></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">H&amp;P:</b> meds, contrast, or other nephrotoxins; ↓ PO intake, HoTN, infxn/sepsis; trauma, myalgias; BPH/retention. Search for insult 24–48 hr prior ↑ Cr. VS, vol status, rash.</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Urine evaluation:</b> output, urinalysis, <b class="calibre4">sediment</b>, electrolytes, and osmolality</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Fractional excretion Na (FE<sub class="calibre8">Na</sub>)</b> = (U<sub class="calibre8">Na</sub>/P<sub class="calibre8">Na</sub>)/(U<sub class="calibre8">Cr</sub>/P<sub class="calibre8">Cr</sub>); if diuretic, ✔ FE<sub class="calibre8">UN</sub>=(U<sub class="calibre8">UN</sub>/P<sub class="calibre8">UN</sub>)/(U<sub class="calibre8">Cr</sub>/P<sub class="calibre8">Cr</sub>)</p>
<p class="bl"><span class="sbl">•</span> Renal U/S or CT: r/o obstruction &amp; cortical atrophy in chronic kidney disease</p>
<p class="bl"><span class="sbl">•</span> Serologies (if indicated): see “Glomerular Disease”</p>
<p class="bl"><span class="sbl">•</span> Renal biopsy (microscopy, IF, and EM): if etiology unclear (esp. if proteinuria/hematuria). Relative contraindic.: SBP&gt;150, ASA/NSAID, anticoag, cirrhosis. DDAVP if GFR &lt;45.</p>
<table class="t-topbot1">
<colgroup class="calibre9">
<col class="calibre57"/>
<col class="calibre28"/>
<col class="calibre58"/>
</colgroup>
<tr class="calibre12">
<td class="bg1-b" colspan="3"><p class="tabheadc"><b class="calibre4">Etiologies and Diagnosis of Acute Kidney Injury</b> <span class="tfont1">(</span><span class="tfont1"><i class="calibre3">Lancet</i></span> <span class="tfont1">20</span><span class="tfont1">1</span><span class="tfont1">2;380:756)</span></p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br" colspan="2"><p class="tab"><b class="calibre4">Etiologies</b></p></td>
<td class="bg0-b"><p class="tab"><b class="calibre4">UA, Sediment, Indices</b></p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br2"><p class="tabc"><b class="calibre4">Prerenal</b></p></td>
<td class="bg0-br"><p class="tabh">↓ <b class="calibre4">Effective arterial volume</b> <span class="tfont1">(</span><span class="tfont1"><i class="calibre3">NEJM</i></span> <span class="tfont1">2007;357:797)</span> Hypovolemia, ↓ CO (CHF), ↓ oncotic pressure (cirrhosis, nephrotic), vasodilation (sepsis)</p>
<p class="tabh">Δ <b class="calibre4">local renal perfusion:</b> NSAIDs, ACEI/ARB, contrast, calcineurin inhib, HRS, hyperCa</p>
<p class="tabh"><b class="calibre4">Large vessel:</b> RAS (bilateral + ACEI), VTE, dissection, abd compart. synd. (renal vs. compress), vasculitis</p></td>
<td class="bg0-b"><p class="tab">Bland</p>
<p class="tab">Transparent hyaline casts</p>
<p class="tab">FE<sub class="calibre13">Na</sub> &lt;1%, BUN/Cr &gt;20</p>
<p class="tab">FE<sub class="calibre13">UN</sub> ≤35%</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br2" rowspan="4"><p class="tabc"><b class="calibre4">Intrinsic</b></p></td>
<td class="bg0-br"><p class="tab"><b class="calibre4">Acute tubular necrosis (ATN)</b></p>
<p class="tab"><i class="calibre3">Severe ischemia, sepsis, CIN</i> (↓ RBF + toxin)</p>
<p class="tab"><i class="calibre3">Toxins</i></p>
<p class="tabh1">Drugs: vanc, AG, cisplatin, foscarnet, HES (starch), IVIG, pentamidine, amphotericin, tenofovir</p>
<p class="tabh1">Pigments: Hb, myoglobin <span class="tfont1">(</span><span class="tfont1"><i class="calibre3">NEJM</i></span> <span class="tfont1">2009;36</span><span class="tfont1">1</span><span class="tfont1">:62)</span></p>
<p class="tabh1">Monoclonal: Ig light chains <span class="tfont1">(</span><span class="tfont1"><i class="calibre3">Blood</i></span> <span class="tfont1">20</span><span class="tfont1">1</span><span class="tfont1">0;</span><span class="tfont1">11</span><span class="tfont1">6:</span><span class="tfont1">1</span><span class="tfont1">397)</span></p>
<p class="tabh1">Crystals: UA, ACV, MTX, indinavir, oral NaPO<sub class="calibre13">4</sub></p></td>
<td class="bg0-b">
<p class="tabh">Pigmented granular muddy brown casts in ~75%</p>
<p class="tabh">± RBCs &amp; protein from tubular damage</p>
<p class="tabh">FE<sub class="calibre13">Na</sub> &gt;2%, BUN/Cr &lt;20 (except pigment, CIN)</p>
<p class="tab">FE<sub class="calibre13">UN</sub> &gt;50%</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br2"><p class="tab"><b class="calibre4">Acute interstitial nephritis (AIN)</b></p>
<p class="tab"><i class="calibre3">Allergic:</i> β-lactams, sulfa drugs, NSAIDs, PPIs</p>
<p class="tab"><i class="calibre3">Infection:</i> pyelo, viral, legionella, TB, leptospirosis</p>
<p class="tab"><i class="calibre3">Infiltrative:</i> sarcoid, lymphoma, leukemia</p>
<p class="tab"><i class="calibre3">Autoimmune:</i> Sjögren’s, TINU syndrome, IgG4, SLE</p></td>
<td class="bg0-b"><p class="tabh">WBCs, WBC casts, ± RBCs w/ neg UCx</p>
<p class="tab">⊕ urine eos in abx</p>
<p class="tab">⊕ lymphs in NSAIDs</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tabh"><b class="calibre4">Small-med vessel:</b> chol emboli, PAN, TMAs (TTP, HUS, atypical HUS, DIC, preeclampsia, APS, malignant HTN, scleroderma renal crisis)</p></td>
<td class="bg0-b"><p class="tab">± RBCs</p>
<p class="tab">⊕ urine eos in chol emboli</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Glomerulonephritis</b> (see “Glomerular Disease”)</p></td>
<td class="bg0-b"><p class="tab">Dysmorphic RBCs, RBC casts</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-r1"><p class="tabc"><b class="calibre4">Post</b></p></td>
<td class="bg0-r"><p class="tabh"><b class="calibre4">Bladder neck:</b> BPH, prostate cancer, neurogenic bladder, anticholinergic meds</p>
<p class="tabh"><b class="calibre4">Ureteral</b> (bilateral or unilateral in single kidney): malig, LAN, retroperitoneal fibrosis, nephrolithiasis</p></td>
<td class="bg"><p class="tab">Bland ± non-dysmorphic RBCs, WBC, crystals</p></td>
</tr>
</table>
<p class="h2a"><b class="calibre4">General treatment</b> <span class="s">(<i class="calibre3">CJASN</i> 2008;3:962)</span></p>
<p class="bl"><span class="sbl">•</span> Prerenal: isotonic IVF ≈ alb <span class="s1r">(<i class="calibre3">NEJM</i> 2004;350:22)</span>. May be benefit to balanced crystalloids (LR) in ICU <span class="s">(<i class="calibre3">NEJM</i> 2018;378:829)</span>.</p>
<p class="bl"><span class="sbl">•</span> Avoid nephrotoxic insults (meds and contrast); renally dose medications</p>
<p class="bl"><span class="sbl">•</span> Optimize hemodynamics (both MAP &amp; CO) and maintain euvolemia <span class="s">(<i class="calibre3">NEJM</i> 2007;357:797)</span></p>
<p class="bl"><span class="sbl">•</span> <i class="calibre3">No</i> benefit to dopamine <span class="s">(<i class="calibre3">Annals</i> 2005;142:510)</span>, diuretics <span class="s">(<i class="calibre3">JAMA</i> 2002;288:2547)</span>, or mannitol</p>
<p class="h2a"><b class="calibre4">Managing complications</b></p>
<p class="bl"><span class="sbl">•</span> May take 1–3 wk to recover from ATN; anticipate volume overload, ↑ K, ↑ PO<sub class="calibre8">4</sub>, acidosis</p>
<p class="bl"><span class="sbl">•</span> Episodes of AKI ↑ risk of CKD progression, even after recovery <span class="s">(<i class="calibre3">NEJM</i> 2014;371:58)</span></p>
<p class="bl"><span class="sbl">•</span> Indications for urgent dialysis (when condition refractory to conventional therapy)</p>
<p class="bl1"><b class="calibre4">A</b>cid-base disturbance: refractory acidemia</p>
<p class="bl1"><b class="calibre4">E</b>lectrolyte disorder: hyperK; hyperCa, hyperPO<sub class="calibre8">4</sub>, tumor lysis syndrome</p>
<p class="bl1"><a id="page_4-13" class="calibre1"></a><b class="calibre4">I</b>ntoxications (<a href="http://www.extrip-workgroup.org/" class="calibre1">http://www.extrip-workgroup.org/</a>): Poison Control (1-800-222-1222)</p>
<p class="bl4">Indicated for: methanol, ethylene glycol, metformin, Li, valproic acid, salicylates, barbiturates, theophylline, thallium</p>
<p class="bl4">Consider for: carbamazepine, APAP, dig (Rx Digibind), dabigatran, (Rx idarucizumab)</p>
<p class="bl1"><b class="calibre4">O</b>verload: refractory hypervolemia → hypoxemia (eg, CHF)</p>
<p class="bl1"><b class="calibre4">U</b>remia: pericarditis, encephalopathy, bleeding</p>
<p class="bl"><span class="sbl">•</span> No mortality benefit to early initiation of RRT <span class="s">(<i class="calibre3">NEJM</i> 2016;375:122 &amp; <i class="calibre3">Jama</i> 2018;379:1431)</span></p>
<p class="h">D<small class="calibre30">ISEASE</small>-S<small class="calibre30">PECIFIC</small> M<small class="calibre30">ANAGEMENT</small></p>
<p class="h2a"><b class="calibre4">Acute interstitial nephritis</b> <span class="s">(AIN) <span class="tfont1">(<i class="calibre3">CJASN</i> 2017;12:2046)</span></span></p>
<p class="bl"><span class="sbl">•</span> Commonly drug-induced: β-lactams, sulfa drugs, NSAIDs, PPIs, quinolones, allopurinol</p>
<p class="bl"><span class="sbl">•</span> If suspected, prompt removal of offending drug; ? early steroids w/in 7d of dx</p>
<p class="h2a"><b class="calibre4">Cardiorenal syndrome</b> <span class="s">(CRS) <span class="tfont1">(<i class="calibre3">CJASN</i> 2017;12:1624)</span></span></p>
<p class="bl"><span class="sbl">•</span> Multifactorial pathophys including: 1) ↓ CO, 2) ↑ renal venous congestion, 3) ↑ RAAS</p>
<p class="bl"><span class="sbl">•</span> Bidirectionality: acute CHF → AKI, and oliguric AKI can worsen CHF <span class="s">(<i class="calibre3">JACC</i> 2008;52:1527)</span></p>
<p class="bl"><span class="sbl">•</span> Rx: <b class="calibre4">IV loop diuretics</b> (bypass gut edema; dosing below); no diff. between high vs. low dose and bolus vs. gtt <span class="s">(<i class="calibre3">NEJM</i> 2011;364:797)</span>. No clinical benefit: dopa, nesiritide, ultrafilt.</p>
<p class="bl"><span class="sbl">•</span> Prognosis: 7% ↑ mortality a/w each 10 mL/min ↓ eGFR in ADHF <span class="s">(<i class="calibre3">JACC</i> 2006;47:1987)</span></p>
<p class="h2a"><b class="calibre4">Contrast-induced acute kidney injury</b> <span class="s">(CIAKI) <span class="tfont1">(<i class="calibre3">NEJM</i> 2019;380:2146)</span></span></p>
<p class="bl"><span class="sbl">•</span> Risk factors: CKD, DM, CHF, age, hypotension, ↑ contrast volume <span class="s">(<i class="calibre3">JACC</i> 2004;44:1393)</span></p>
<p class="bl"><span class="sbl">•</span> AKI 24–48 h post contrast, peaks 3–5 d, resolves 7–10 d (consider chol emboli if does not)</p>
<p class="bl"><span class="sbl">•</span> Prevention: consider if eGFR &lt;60 (espec. w/ proteinuria), DM, MI, HoTN <span class="s1r">(<i class="calibre3">CJASN</i> 2013;8:1618)</span></p>
<p class="bl2"><b class="calibre4">Isotonic IV fluids:</b> data mixed, but may be helpful if high risk <span class="s1r">(<i class="calibre3">Int Med</i> 2014;53:2265; <i class="calibre3">Lancet</i> 2017;389:1312)</span>. No benefit to NaHCO<sub class="calibre8">3</sub> over NaCl <span class="s1r">(<i class="calibre3">NEJM</i> 2018;378:603)</span>.</p>
<p class="bl2">Outpatients: 3 mL/kg/h × 1h prior, 1–1.5 mL/kg/h × 6h after <span class="s1r">(<i class="calibre3">JAMA</i> 2004;291:2328)</span></p>
<p class="bl2">Inpatients: 1 mL/kg/h × 6–12 h pre, intra, post-procedure <span class="s1r">(<i class="calibre3">Lancet</i> 2014;383:1814)</span></p>
<p class="bl1">Hold ACEI/ARB <span class="s1r">(<i class="calibre3">AJKD</i> 2012;60:576)</span>, NSAIDs, diuretics. Min. contrast &amp; use iso-osmolar.</p>
<p class="bl1">No benefit to NAC <span class="s1r">(<i class="calibre3">NEJM</i> 2018;378:603)</span> or preemptive RRT <span class="s1r">(<i class="calibre3">Am J Med</i> 2012;125:66)</span></p>
<p class="bl"><span class="sbl">•</span> Nephrogenic systemic fibrosis: fibrosis of skin, joints, internal organs ~2–4 wk post gado exposure in CKD 4–5 <span class="s1r">(<i class="calibre3">JACC</i> 2009;53:1621)</span>. Postgado HD encouraged, though limited data.</p>
<p class="h2a"><b class="calibre4">Diabetic nephropathy</b> <span class="s">(<i class="calibre3">NEJM</i> 2016;375:2096)</span></p>
<p class="h2a"><b class="calibre4">Hepatorenal syndrome</b> <span class="s">(HRS; see “Cirrhosis”; <i class="calibre3">AJKD</i> 2013;62:1198)</span></p>
<p class="bl"><span class="sbl">•</span> Albumin + <i class="calibre3">either</i> IV vasopressors (norepi, terlipressin) <i class="calibre3">or</i> octreotide &amp; midodrine</p>
<p class="h2a"><b class="calibre4">Obstructive diseases</b></p>
<p class="bl"><span class="sbl">•</span> Dx: renal U/S if undifferentiated or CT abd/pelvic (I<sup class="calibre15">–</sup>) if suspect nephrolithiasis</p>
<p class="bl"><span class="sbl">•</span> Rx: Foley if urethra vs. perc. nephrostomy if above ureters (eg, stones), tamsulosin/finasteride</p>
<p class="bl"><span class="sbl">•</span> Watch for post-obstructive diuresis after relieving blockage, replace ½ UOP w/ ½ NS.</p>
<p class="bl1">Hemorrhagic cystitis (rapid ∆ in size of bladder vessels); avoid by decompressing slowly.</p>
<p class="h2a"><b class="calibre4">Polycystic kidney disease</b> <span class="s">(<i class="calibre3">NEJM</i> 2004;350:151; 2008;359:1477; 2017;377:1988)</span></p>
<p class="bl"><span class="sbl">•</span> Mostly AD <i class="calibre3">PKD1/PKD2</i> mutations → renal cysts. PKD1 (85%) younger-onset ESRD.</p>
<p class="bl"><span class="sbl">•</span> Rx: hydration, low-salt diet; tolvaptan reduces GFR decline. Family genetic screening.</p>
<p class="h2a"><b class="calibre4">Rhabdomyolysis</b> <span class="s">(<i class="calibre3">NEJM</i> 2009;361:62)</span></p>
<p class="bl"><span class="sbl">•</span> Pathophys: myoglobin-induced oxidant injury, vasoconstriction, myoglobin precipitation &amp; pre-renal (extravasation). Can lead to ↓ Ca, ↑ K, and ↑ PO<sub class="calibre8">4</sub>.</p>
<p class="bl"><span class="sbl">•</span> Diagnosis: UA ⊕ for heme but 0 RBCs (ie, myoglobinuria)</p>
<p class="bl"><span class="sbl">•</span> Risk of AKI when CK &gt;20,000. Rhabdo and mortality risk score: <i class="calibre3">JAMA Int Med</i> 2013;173:1821.</p>
<p class="bl"><span class="sbl">•</span> Aggressive IVF (tailor IVF to target UOP ~3 mL/kg). If urine pH &lt;6.5, consider NaHCO<sub class="calibre8">3</sub> ✔ K &amp; Ca frequently, trend CK. Monitor for compartment syndrome.</p>
<p class="h2a"><b class="calibre4">Scleroderma renal crisis</b> <span class="s">(<i class="calibre3">Nature Neph</i> 2016;12:678)</span></p>
<p class="bl"><span class="sbl">•</span> 5–20% diffuse cutaneous SSc w/ narrowing glomerular vessels. Sx: renal failure, severe HTN, encephalopathy. Rx: max ACEi for BP control.</p>
<p class="h2a"><b class="calibre4">Thrombotic microangiopathies</b> <span class="s2">(TMAs):</span> <i class="calibre3">see “Hematology”</i></p>
<p class="h">C<small class="calibre30">HRONIC</small> K<small class="calibre30">IDNEY</small> D<small class="calibre30">ISEASE</small> (CKD)</p>
<p class="h2a"><b class="calibre4">Definition and etiologies</b> <span class="s">(<i class="calibre3">Lancet</i> 2012;379:165; <i class="calibre3">JAMA</i> 2015;313:837)</span></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">GFR</b> &lt;60 for ≥3 mo <i class="calibre3">and</i>/<i class="calibre3">or</i> <b class="calibre4">kidney damage</b> (albuminuria, structural abnormality)</p>
<p class="bl"><span class="sbl">•</span> Prevalence 15% in U.S.</p>
<p class="bl"><span class="sbl">•</span> Albuminuria predicts all-cause &amp; CV mortality, CKD progression <span class="s">(<i class="calibre3">NEJM</i> 2004;351:1296)</span></p>
<p class="bl"><span class="sbl">•</span> Cr poor estimate of GFR, use equation (<a href="http://www.kidney.org/professionals/KDOQI/gfr_calculator.cfm" class="calibre1">www.kidney.org/professionals/KDOQI/gfr_calculator.cfm</a>)</p>
<p class="bl1">CKD-EPI preferred over MDRD because less likely to underestimate at normal GFRs</p>
<p class="bl1">cystatin-C–based formulae perform better than Cr-based <span class="s1r">(<i class="calibre3">NEJM</i> 2012;367:20)</span></p>
<p class="bl"><a id="page_4-14" class="calibre1"></a><span class="sbl">•</span> Etiologies: DM (45%), HTN/RAS (27%), glomerular (10%), interstitial (5%), PKD (2%) <span class="s">(<i class="calibre3">NEJM</i> 2008;359:1477; <i class="calibre3">AJKD</i> 2019;73:A7)</span>, congenital, drugs, myeloma <span class="s">(<i class="calibre3">JAMA</i> 2009;302:1179)</span>, repeated insults (eg, Mesoamerican nephropathy <i class="calibre3">AJKD</i> 2018;72:469)</p>
<p class="bl"><span class="sbl">•</span> Progression to ESRD: kidney failure risk equation <span class="s">(<i class="calibre3">JAMA</i> 2016;315:164)</span></p>
<table class="t-topbot1">
<colgroup class="calibre9">
<col class="calibre33"/>
<col class="calibre29"/>
<col class="calibre43"/>
</colgroup>
<tr class="calibre12">
<td class="bg1-b" colspan="3"><p class="tabheadc"><b class="calibre4">Stages of CKD</b> <span class="tfont1">(</span><span class="tfont1"><i class="calibre3">Kid Int</i></span> <span class="tfont1">20</span><span class="tfont1">1</span><span class="tfont1">3;3[Suppl]:5)</span></p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">GFR Stage</b></p></td>
<td class="bg0-br"><p class="tabc"><b class="calibre4">GFR</b> mL/min/1.73 m<sup class="calibre35">2</sup></p></td>
<td class="bg0-b"><p class="tab"><b class="calibre4">Goals</b></p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab">1 (nl or ↑ GFR)</p></td>
<td class="bg0-br"><p class="tabc">&gt;90</p></td>
<td class="bg0-b"><p class="tab">Dx/Rx of underlying condition &amp; comorbidities, slow progression; cardiovascular risk reduction</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab">2 (mild)</p></td>
<td class="bg0-br"><p class="tabc">60–89</p></td>
<td class="bg0-b"><p class="tab">Estimate progression</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab">3a (mild-mod)</p></td>
<td class="bg0-br"><p class="tabc">45–59</p></td>
<td class="bg0-b"><p class="tab">Evaluate and treat complications</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab">3b (mod-severe)</p></td>
<td class="bg0-br"><p class="tabc">30–44</p></td>
<td class="bg0-b"><p class="tab">Evaluate and treat complications</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab">4 (severe)</p></td>
<td class="bg0-br"><p class="tabc">15–29</p></td>
<td class="bg0-b"><p class="tab">Prepare for renal replacement therapy (RRT)</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab">5 (kidney failure)</p></td>
<td class="bg0-br"><p class="tabc">&lt;15 or dialysis</p></td>
<td class="bg0-b"><p class="tab">Dialysis if uremic/volume overload; Tx</p></td>
</tr>
<tr class="calibre12">
<td class="bg" colspan="3"><p class="tab"><b class="calibre4">Albuminuria stage</b> based on albuminuria (mg/d) or spot urine alb (mg) to Cr (g) ratio</p>
<p class="tab">Stages: A1 = &lt;30 (normal/mild); A2 = 30–300 (moderate); A3 = &gt;300 (severe)</p></td>
</tr>
</table>
<table class="t-topbot1">
<colgroup class="calibre9">
<col class="calibre33"/>
<col class="calibre34"/>
</colgroup>
<tr class="calibre12">
<td class="bg1-b" colspan="2"><p class="tabheadc"><b class="calibre4">Signs and Symptoms of Uremia</b> <span class="tfont1">(</span><span class="tfont1"><i class="calibre3">NEJM</i></span> <span class="tfont1">20</span><span class="tfont1">1</span><span class="tfont1">8;379:669)</span></p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab">General</p></td>
<td class="bg0-b"><p class="tab">Nausea, anorexia, malaise, uremic fetor, metallic taste, hypothermia</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab">Skin</p></td>
<td class="bg0-b"><p class="tab">Uremic frost (white crystals in &amp; on skin), pruritus, calciphylaxis</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab">Neurologic</p></td>
<td class="bg0-b"><p class="tab">Encephalopathy (Δ MS, ↓ memory &amp; attention), seizures, neuropathy, impaired sleep, restless leg syndrome</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab">Cardiovascular</p></td>
<td class="bg0-b"><p class="tab">Pericarditis, atherosclerosis, HTN, CHF, cardiomyopathy (LVH)</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab">Hematologic</p></td>
<td class="bg0-b"><p class="tab">Anemia, bleeding (due to platelet dysfunction and Epo deficiency)</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-r"><p class="tab">Metabolic</p></td>
<td class="bg"><p class="tab">↑ K, ↑ PO<sub class="calibre13">4</sub>, acidosis, ↓ Ca, 2° hyperparathyroidism, osteodystrophy</p></td>
</tr>
</table>
<p class="h2a"><b class="calibre4">Complications &amp; treatment</b> <span class="s">(KDIGO 2013)</span></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">General:</b> renal referral when GFR &lt;30 or proteinuria, access planning (avoid subclavian lines, preserve an arm by avoiding phlebotomy, BP measurements, IVs)</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">CV risk reduction:</b> consider usual preventive Rx including statin, βB, etc.</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Dietary restrictions:</b> Na (if HTN), K (if oliguric or hyperkalemic), PO<sub class="calibre8">4</sub>, mod protein.</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Diabetes:</b> strict glc control; SGLT2i slow CKD progression <span class="s1r">(<i class="calibre3">NEJM</i> 2017;377:1765 &amp; 2019;380:2295)</span></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">BP control:</b> goal &lt;130/80, a/w ↓ mortality <span class="s">(<i class="calibre3">NEJM</i> 2015;373:2103; <i class="calibre3">JASN</i> 2017;28:2812)</span>. ACEI or ARB (NEJM 2004;351:1952), not both <span class="s">(<i class="calibre3">NEJM</i> 2013;369:1892)</span>. For outPts, ✔ Cr &amp; K in 1–2 wk, d/c if Cr ↑ 30% or K &gt;5.4 (after dietary Δ &amp; loop diuretic).</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Metabolic acidosis:</b> sodium bicarbonate or sodium citrate if low HCO<sub class="calibre8">3</sub> <span class="s1r">(<i class="calibre3">JASN</i> 2015;26:515)</span></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Hyperkalemia:</b> 2-g K diet, see “Potassium Homeostasis”</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Anemia:</b> goal Hb 10–11.5 g/dL, worse outcomes if target higher <span class="s">(<i class="calibre3">NEJM</i> 2009;361:2019)</span></p>
<p class="bl1">epoetin (start 80–120 U/kg SC, divided 3×/wk) or darbepoetin (0.75 mg/kg q 2wk)</p>
<p class="bl1">iron supplementation to keep transferrin sat &gt;20% (often given IV in HD Pts)</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Uremic bleeding:</b> desmopressin (dDAVP) 0.3 μg/kg IV or 3 μg/kg intranasally</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">2</b>° <b class="calibre4">hyperPTH:</b> ↑ PO<sub class="calibre8">4</sub>, ↓ Ca, ↓ calcitriol, ↑ FGF-23 → ↑ PTH → renal osteodystrophy</p>
<p class="image1"><img src="../images/00075.jpeg" alt="" class="calibre2"/></p>
<p class="bl1">Phosphorus binders (<i class="calibre3">take with meals!</i>) <span class="s">(<i class="calibre3">NEJM</i> 2010;362:1312)</span></p>
<p class="bl4">Consider sevelamer first, Ca acetate &amp; lanthanum other options. Non-Ca–based binders a/w ↓ mort. compared to Ca-based <span class="s">(<i class="calibre3">Lancet</i> 2013;382:1268)</span>.</p>
<p class="bl1">If PTH above goal then start vit. D (if 25-(OH)D &lt;30) or 1,25-(OH)D analogue (calcitriol); stop if ↑ Ca <span class="s">(<i class="calibre3">AJKD</i> 2009;53:408)</span></p>
<p class="bl1">Cinacalcet (parathyroid Ca-sensing receptor agonist) if ↑ PTH despite phosphorus binders ± vit. D analogue <span class="s">(<i class="calibre3">CJASN</i> 2016;11:161)</span>; consider parathyroidectomy</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Calciphylaxis</b> (calcific uremic arteriopathy, <i class="calibre3">NEJM</i> 2018;378:1704)</p>
<p class="bl1">Pathophys: calcification of media in dermal small- to med-sized blood vessels &amp; SC fat → ischemia and skin necrosis w/ painful lesions <span class="s1r">(<i class="calibre3">NEJM</i> 2007;356:1049)</span></p>
<p class="bl1">Risk factors: ESRD, ♀&gt;♂, DM, vit K def, obesity, warfarin, local trauma, thrombophilias</p>
<p class="bl1">Dx: skin bx, but limitations <span class="s1r">(<i class="calibre3">Kidney Int</i> 2018;94:390)</span>; bone scan used in support of dx</p>
<p class="bl1">Rx: ↓ risk factors, wound care/surgical debridement, Na thiosulfate <span class="s1r">(<i class="calibre3">CJASN</i> 2013;8:1162)</span>, manage hyperPTH, no vit D &amp; Ca, NOACs &gt; warfarin, pain control, palliative care</p>
<p class="bl1">Prognosis: 60% 1-y mortality in ESRD Pts <span class="s1r">(<i class="calibre3">AJKD</i> 2015;66:133)</span></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Anticoag:</b> ESRD at ↑ bleed risk; if using DOAC, consider apixiban &gt; rivaroxaban &gt; dabigatran due to protein binding/renal clearance <span class="s">(<i class="calibre3">JASN</i> 2017;28:2241)</span></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Transplant evaluation</b></p>
<p class="h"><a id="page_4-15" class="calibre7"></a>D<small class="calibre30">IURESIS</small></p>
<p class="h2a"><b class="calibre4">General considerations</b></p>
<p class="bl"><span class="sbl">•</span> ↑ Na &amp; H<sub class="calibre8">2</sub>O excretion for treatment of HTN or edema in CHF, renal failure, and cirrhosis</p>
<p class="bl"><span class="sbl">•</span> Daily wt most effective method of documenting successful diuresis</p>
<p class="h2a"><b class="calibre4">Loop diuretics</b> <span class="s">(<i class="calibre3">NEJM</i> 2017;377:1964)</span></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Drugs:</b> furosemide (Lasix), torsemide, bumetanide (Bumex), ethacrynic acid</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Mech:</b> inhib NaK2Cl cotransporter in thick ascending limb (ThAL, site of 25% Na reabsorp) → ↓ medullary osmotic gradient &amp; ↓ free H<sub class="calibre8">2</sub>O reabsorption via ADH</p>
<p class="bl1">Transient venodilation may aid in pulmonary congestion (<i class="calibre3">NEJM 1</i>973;288:1087)</p>
<p class="bl1">Response is fxn of amt of drug excreted; ∴ ↑ dose needed in renal insufficiency, CHF</p>
<p class="bl1">Sigmoidal dose response curve; ∴ ↑ dose until induce diuresis, ↑↑ dose beyond that point yields diminishing returns compared with ↑ frequency of dosing</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Dosing:</b> bioavailability PO furosemide ~50%, PO torsemide &amp; bumetanide ~90%</p>
<p class="bl1">40 mg IV = 80 mg PO Lasix = 20 mg PO/IV torsemide = 1 mg IV/PO bumetanide</p>
<p class="bl1">Dose furosemide bid-qid; qd dosing can yield initial diuresis, but then anti-natriuresis. Cont. vs. bolus IV similar in acute CHF <span class="s1r">(<i class="calibre3">NEJM</i> 2011;364:797)</span>. Ethacrynic acid if sulfa allergy.</p>
<p class="bl1">? ↑ diuresis w/ co-administration of albumin if ↓ serum albumin <span class="s1r">(<i class="calibre3">Crit Care Med</i> 2005;33:1681)</span></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Adverse effects:</b> ↑ Na, ↓ K, ↓ Mg, ↓ Ca, hyperuricemia, ototoxicity, hypersensitivity (sulfa)</p>
<p class="h2a"><b class="calibre4">Thiazide diuretics</b> <span class="s">(<i class="calibre3">JASN</i> 2017;28:3414)</span></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Drugs:</b> hydrochlorothiazide (HCTZ), chlorothiazide (Diuril), metolazone (Zaroxolyn)</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Mech:</b> inhib Na-Cl cotransporter in the distal convoluted tubule (DCT); 5% Na reabsorp</p>
<p class="bl1"><b class="calibre4">synergistic with loop diuretic</b>, esp. if chronic loop use</p>
<p class="bl1">↓ effect when GFR &lt;30, <i class="calibre3">except metolazone</i>, which is still effective in renal insufficiency</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Dosing:</b> give 30 min prior to loop diuretic</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Adverse effects:</b> ↓ Na, ↓ K, ↓ Mg, ↑ Ca, HLD, pancreatitis, ↑ glc, hypersensitivity</p>
<p class="h2a"><b class="calibre4">K-sparing diuretics</b> <span class="s">(<i class="calibre3">NEJM</i> 2017;377:1964)</span></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Drugs:</b> spironolactone (Aldactone), amiloride, triamterene, eplerenone</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Mech:</b> ↓ Na reabsorption (~1%) in collecting duct (amiloride/triamterene inhibit principal cell Na channel [ENaC]; spironolactone/eplerenone inhibit mineralocorticoid receptor).</p>
<p class="bl1">Relatively weak natriuretic activity, useful in combination with thiazide or in cirrhosis.</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Adverse effects:</b> ↑ K (esp. w/ ACEI), metabolic acidosis, gynecomastia (spironolactone)</p>
<table class="t-topbot1">
<colgroup class="calibre9">
<col class="calibre37"/>
<col class="calibre59"/>
</colgroup>
<tr class="calibre12">
<td class="bg1-b" colspan="2"><p class="tabheadc"><b class="calibre4">Approach to Diuresis</b> <span class="s2">(if inadequate diuresis, go to next step)</span></p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tabc"><b class="calibre4">Step</b></p></td>
<td class="bg0-b"><p class="tab"><b class="calibre4">Action</b></p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tabc">1</p></td>
<td class="bg0-b"><p class="tab"><b class="calibre4">Loop diuretic PO:</b> ✔ response at 1–3 h, redose at 2× prior dose if needed</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tabc">2</p></td>
<td class="bg0-b"><p class="tab"><b class="calibre4">Add thiazide diuretic PO</b> (potentiates response to loop diuretic)</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tabc">3</p></td>
<td class="bg0-b"><p class="tab"><b class="calibre4">Loop diuretic IV:</b> bolus bid–qid ± thiazide (<i class="calibre3">may start here if inPt</i>) ↑ dose w/ ↑ Cr; initial effective IV Lasix dose ≈ 30 × Cr (ie, if Cr = 4 → 120 mg IV)</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tabc">4</p></td>
<td class="bg0-b"><p class="tab"><b class="calibre4">Loop diuretic infusion:</b> bolus + continuous IV infusion ± thiazide (PO or IV)</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-r"><p class="tabc">5</p></td>
<td class="bg"><p class="tab"><b class="calibre4">RRT:</b> consider ultrafiltration, CVVH, or HD</p></td>
</tr>
</table>
<p class="h2a"><b class="calibre4">Disease state specific regimens</b></p>
<p class="bl"><span class="sbl">•</span> Renal insufficiency: loop diuretic (↑ dose to achieve effective delivery to ThAL) ± thiazide</p>
<p class="bl"><span class="sbl">•</span> CHF: loop diuretic (↑ frequency over ↑ dose), IV for gut edema + thiazide (watch K &amp; Mg)</p>
<p class="bl"><span class="sbl">•</span> Nephrotic syndrome: urinary albumin binds secreted loop diuretic, use 2–3× normal dose</p>
<p class="bl"><span class="sbl">•</span> Cirrhosis: spironolactone (blocks 2° hyperaldosteronism) + Lasix in 2.5:1 ratio</p>
<p class="bl"><span class="sbl">•</span> Severe metabolic alkalosis: acetazolamide &amp; treat underlying cause</p>
<p class="h">R<small class="calibre30">ENAL</small> R<small class="calibre30">EPLACEMENT</small> <small class="calibre30">AND</small> D<small class="calibre30">IALYSIS</small></p>
<p class="h2a"><b class="calibre4">General</b></p>
<p class="bl"><span class="sbl">•</span> Acute indications: see “AKI”; choices CVVH vs. HD</p>
<p class="bl"><span class="sbl">•</span> Chronic indications: timing of RRT initiation should factor in Pt QoL, uremic sx, risk of development of urgent/acute indications; modalities PD vs. HD (no clear diff in outcomes)</p>
<p class="bl"><span class="sbl">•</span> Outcomes of ESRD: death from CVD (50%), infxn (30%), withdrawal of care (20%)</p>
<p class="imagef"><img src="../images/00076.jpeg" alt="" class="calibre2"/></p>
<p class="fn"><span class="tfont1">*Disequilibrium syndrome: sx cerebral edema due to H</span><sub class="calibre13">2</sub><span class="tfont1">O shifts after urea removal</span></p>
<p class="h2a"><a id="page_4-16" class="calibre1"></a><b class="calibre4">Hemodialysis (HD)</b> <span class="s">(<i class="calibre3">NEJM</i> 2010;363:1833)</span></p>
<p class="bl"><span class="sbl">•</span> Solute removal across <i class="calibre3">semipermeable</i> membrane, countercurrent blood &amp; dialysate flow</p>
<p class="bl1">Volume removal: Na/H<sub class="calibre8">2</sub>O ultrafiltered via transmembrane pressure (TMP) gradient</p>
<p class="bl1">Solutes: Cr, urea, K diffuse from blood → dialysate, HCO<sub class="calibre8">3</sub> from dialysate → blood</p>
<p class="bl1">Solute removal inversely proportional to size ∴ effective removal of K, urea, Cr, not PO<sub class="calibre8">4</sub></p>
<p class="bl"><span class="sbl">•</span> 6× vs. 3×/wk improved HTN, LV mass, QoL, but ↑ vasc issues <span class="s1r">(<i class="calibre3">NEJM</i> 2010;363:2287)</span>; w/ 3×/wk HD, ↑ mortality risk during 2-d interval (Sa–Tu or Fri–Mo) <span class="s1r">(<i class="calibre3">NEJM</i> 2011;365:1099)</span></p>
<p class="bl"><span class="sbl">•</span> Fever w/ catheter: empiric abx (vanc + GNR coverage qHD). GPC &gt; GNR &gt; mixed/fungal. Remove/replace catheter (depends on organism), “lock” abx <span class="s">(<i class="calibre3">JASN</i> 2014;25:2927)</span>.</p>
<p class="bl"><span class="sbl">•</span> Central vein stenosis: assoc. with longer HD duration, tunneled catheters. HeRO grafts bypass subclavian stenosis with flow into central vein <span class="s">(<i class="calibre3">J Vasc Access</i> 2016;17:138)</span>.</p>
<table class="t-topbot1">
<colgroup class="calibre9">
<col class="calibre41"/>
<col class="calibre17"/>
<col class="calibre36"/>
</colgroup>
<tr class="calibre12">
<td class="bg1-b" colspan="3"><p class="tabheadc"><b class="calibre4">Vascular Access</b></p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"> </p></td>
<td class="bg0-br"><p class="tab"><b class="calibre4">Advantages</b></p></td>
<td class="bg0-b"><p class="tab"><b class="calibre4">Disadvantages</b></p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">AV fistula</b></p></td>
<td class="bg0-br"><p class="tab">Highest patency</p>
<p class="tab">Lowest risk of bacteremia</p>
<p class="tab">Lowest mortality <span class="tfont1">(</span><span class="tfont1"><i class="calibre3">JASN</i></span> <span class="tfont1">20</span><span class="tfont1">1</span><span class="tfont1">3;24:465)</span></p></td>
<td class="bg0-b"><p class="tab">Long maturation time (2–6 mo)</p>
<p class="tab">Primary nonfunction (20%)</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">AV graft</b></p></td>
<td class="bg0-br"><p class="tab">Easier to create than AVF</p>
<p class="tab">Maturation time (2–3 wk)</p></td>
<td class="bg0-b"><p class="tab">Poor 1° patency, often requiring thrombectomy or angioplasty</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-r"><p class="tab"><b class="calibre4">Catheter</b></p></td>
<td class="bg0-r"><p class="tab">Immediate use</p>
<p class="tab">Use as bridge to AVF/AVG</p></td>
<td class="bg"><p class="tab">Highest risk of bacteremia</p>
<p class="tab">↓ blood flow → ↓ HD efficiency</p></td>
</tr>
</table>
<p class="h2a"><b class="calibre4">Continuous veno-venous hemofiltration</b> (CVVH) <span class="s">(<i class="calibre3">NEJM</i> 2012;367:26)</span></p>
<p class="bl"><span class="sbl">•</span> <i class="calibre3">Hemofiltration</i> rather than dialysis. Blood under pressure passes down one side <i class="calibre3">highly permeable</i> membrane filtering H<sub class="calibre8">2</sub>O and solutes via TMP gradient (convective clearance); filtrate discarded. Replacement fluid infused (solute concentration similar to plasma, except no urea, Cr, PO<sub class="calibre8">4</sub>). Fluid balance by adjusting filtrate/replacement fluid.</p>
<p class="bl"><span class="sbl">•</span> Replacement fluid rate determines clearance. Choice of replacement fluid buffer:</p>
<p class="bl1"><b class="calibre4">HCO</b><sub class="calibre8">3</sub> (+ heparin to prevent clotting, although can be run heparin-free)</p>
<p class="bl1"><b class="calibre4">citrate:</b> hepatically metabolized to HCO<sub class="calibre8">3</sub>, ∴ cannot be given in cirrhosis/liver failure. Provides anticoag w/in machine via Ca chelation. Citrate toxicity: ↓ iCa but nl/ ↑ serum Ca and AG met acidosis.</p>
<p class="bl1">Dose adjust for solute and volume removal <span class="s1r">(<i class="calibre3">AJKD</i> 2016;68:645)</span></p>
<p class="bl"><span class="sbl">•</span> Other CRRT modalities: CVVHD (dialysis), CVVHDF (filtration &amp; dialysis) <span class="s1r">(<i class="calibre3">AJKD</i> 2016;68:645)</span></p>
<p class="bl"><span class="sbl">•</span> Benefits compared w/ HD: ↓ gross fluid shift (preferred in HoTN), but slower clearance of solutes and toxins</p>
<p class="h2a"><b class="calibre4">Peritoneal dialysis (PD)</b> <span class="s">(<i class="calibre3">JAMA</i> 2017;317:1864)</span></p>
<p class="bl"><span class="sbl">•</span> Fluid removed via convection using oncotic pressure (eg, dextrose). ↑ concentrations and dwell times removes more fluid (less as glc equilibrates).</p>
<p class="bl"><span class="sbl">•</span> PD fluid: dextrose (1.5%, 2.5%, or 4.25%), buffer (lactate), Na<sup class="calibre15">+</sup>, Ca<sup class="calibre15">2</sup><sup class="calibre15">+</sup>, Mg<sup class="calibre15">2</sup><sup class="calibre15">+</sup></p>
<p class="bl"><span class="sbl">•</span> infuse 10 min, dwell 90 min–5.5 h, drain 20 min; exchanges done manually or using cycler at night (automated or cont. ambulatory peritoneal dialysis APD, CAPD)</p>
<p class="bl"><span class="sbl">•</span> PD peritonitis: abd pain &amp; cloudy drainage (WBC &gt;100 &amp; &gt;50% PMNs). 60–70% GPC, 15– 20% GNR. Rx: abx IV or in PD, catheter removal for certain org (yeast, <i class="calibre3">Pseudomonas</i>).</p>
<p class="bl"><span class="sbl">•</span> Sclerosing peritonitis, a rare long-term complication <span class="s1r">(<i class="calibre3">NEJM</i> 2002; 347:737)</span></p>
<p class="bl"><span class="sbl">•</span> Hyperglycemia: exacerbated by inflammation, long dwell times, and higher [glucose]</p>
<p class="bl"><span class="sbl">•</span> Benefits: lower cost, independence, preservation of residual kidney function. No Δ mortality vs. HD <span class="s">(<i class="calibre3">AJKD</i> 2018;71:344)</span>.</p>
<p class="h2a"><b class="calibre4">Kidney transplantation</b> <span class="s">(<i class="calibre3">Med Clin N Am</i> 2016;100:435)</span></p>
<p class="bl"><span class="sbl">•</span> Refer when GFR &lt;20. Contraindic: active malig, infxn, ischemia, noncompl, subst use</p>
<p class="bl"><span class="sbl">•</span> 5-yr survival: living donor 91%; deceased donor 70–84% <span class="s">(<i class="calibre3">AJKD</i> 2016;23:281)</span>. Donors have minor ↑ risk of ESRD <span class="s">(<i class="calibre3">Am J Transplant</i> 2014;14:2434)</span>.</p>
<p class="bl"><span class="sbl">•</span> Immunosuppression: calcineurin inhib (tacrolimus&gt;CsA) or CTLA4 inhib (belatacept) <span class="s1r">(<i class="calibre3">NEJM</i> 2016;374:333)</span>, antimetabolite (MMF&gt;AZA), prednisone, mTOR inhib (sirolimus) if others contraindicated</p>
<p class="bl"><span class="sbl">•</span> Rejection: Ab (ABMR) or T-cell mediated (TCMR), a/w poor graft survival; BANFF criteria <span class="s">(<i class="calibre3">Am J Transplant</i> 2018;18:293)</span>. Rx options: ↑ immunosupp., pulse steroids, IVIG, rituximab.</p>
<p class="bl"><span class="sbl">•</span> Late renal dysfxn: usual AKI causes + calcineurin tox, rejection <span class="s1r">(<i class="calibre3">NEJM</i> 2010;363:1451)</span>, BK virus, recurrence of 1° disease; usual w/u + immunosupp levels, donor-specific antigen (DSA), BK virus load, U/S, then bx if no other cause <span class="s">(<i class="calibre3">CJASN</i> 2008;3:S56; <i class="calibre3">CJASN</i> 2011;6:1774)</span></p>
<p class="bl"><span class="sbl">•</span> ↑ infxn (incl opportunistic such CMV, JC, BK viruses; <i class="calibre3">CJASN</i> 2012;7:2058) &amp; cancer (PTLD)</p>
<p class="bl"><span class="sbl">•</span> ↑ CVD risk due to HTN (calcineurin inhib, RAS), DM &amp; dyslipidemia (immunosupp meds)</p>
<h2 class="ct"><a id="h58" class="calibre7"></a><a id="page_4-17" class="calibre7"></a><a href="part0002.html#rh65" class="calibre7">GLOMERULAR DISEASE</a></h2>
<p class="h">G<small class="calibre30">LOMERULONEPHRITIS</small> (GN)</p>
<p class="h2a"><b class="calibre4">Definition</b> <span class="s">(<i class="calibre3">Lancet</i> 2016;387:2036; <i class="calibre3">JASN</i> 2016;27:1278)</span></p>
<p class="bl"><span class="sbl">•</span> ↑ glomerular inflammation → endothelial &amp; podocyte injury</p>
<p class="bl"><span class="sbl">•</span> Histology: proliferative (↑ cells), sclerosing (scar), necrotizing (areas cell death). Focal (&lt;50% of glomeruli) to diffuse to crescentic. Segmental (&lt;50% tuft) to global (100%).</p>
<p class="bl"><span class="sbl">•</span> Clinically: hematuria w/ dysmorphic RBCs or RBC casts, ± subnephrotic proteinuria</p>
<p class="bl1">often w/ AKI, HTN, edema</p>
<p class="bl"><span class="sbl">•</span> Progression: acute ≈ days; rapidly progressive (RPGN) ~6 wk; chronic ≈ mos; can be asx</p>
<p class="bl"><span class="sbl">•</span> Crescentic GN (pathologic description) ≈ RPGN (clinical description)</p>
<p class="imagef"><img src="../images/00077.jpeg" alt="" class="calibre2"/></p>
<p class="fn"><sup class="calibre35">a</sup><span class="tfont1">Predominant type; p- or c-ANCA can be in all</span> <span class="tfont1">(<i class="calibre3">NEJM</i> 2012;367:214)</span>; <sup class="calibre35">b</sup><span class="tfont1">GPA (Wegener’s); EGPA (Churg-Strauss)</span></p>
<p class="image1"><img src="../images/00078.jpeg" alt="" class="calibre2"/></p>
<table class="t-topbot1">
<colgroup class="calibre9">
<col class="calibre36"/>
<col class="calibre43"/>
</colgroup>
<tr class="calibre12">
<td class="bg1-b" colspan="2"><p class="tabheadc"><b class="calibre4">Immune Complex (IC) Disease (granular staining) ~40–45% of total</b> <span class="tfont1">(</span><span class="tfont1"><i class="calibre3">CJASN</i></span> <span class="tfont1">20</span><span class="tfont1">1</span><span class="tfont1">8;</span><span class="tfont1">1</span><span class="tfont1">3:</span><span class="tfont1">1</span><span class="tfont1">28)</span></p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Renal-limited Diseases</b></p></td>
<td class="bg0-b"><p class="tab"><b class="calibre4">Systemic Diseases</b></p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Infection-related GN</b></p>
<p class="tab">(<i class="calibre3">Staph</i> &amp; <i class="calibre3">Strep;</i> ↓ C3, ± ASLO)</p></td>
<td class="bg0-b"><p class="tab"><b class="calibre4">SLE</b> (<i class="calibre3">CJASN</i> 2017;12:825)</p>
<p class="tab">(⊕ ANA, ⊕ anti-dsDNA, ⊕ anti-Sm, ↓ C3, ↓ C4)</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Membranoproliferative GN</b> (MPGN) (↓ C3)</p></td>
<td class="bg0-b"><p class="tab"><b class="calibre4">Cryoglobulinemia</b></p>
<p class="tab">(⊕ cryocrit, ⊕ RF, ⊕ HCV, SPEP, ↓ C3, ↓ C4)</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Fibrillary and immunotactoid GN</b> (normal C3/C4)</p></td>
<td class="bg0-b"><p class="tab"><b class="calibre4">Endocarditis</b></p>
<p class="tab">(fever, ⊕ BCx, valvular disease, ↓ C3)</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-r"><p class="tab"><b class="calibre4">IgA nephropathy</b> (normal C3, ±↑ IgA)</p>
<p class="tab"><span class="tfont1">(</span><span class="tfont1"><i class="calibre3">NEJM</i></span> <span class="tfont1">20</span><span class="tfont1">1</span><span class="tfont1">3;368:2402;</span> <span class="tfont1"><i class="calibre3">CJASN</i></span> <span class="tfont1">20</span><span class="tfont1">1</span><span class="tfont1">7;</span><span class="tfont1">1</span><span class="tfont1">2:677)</span></p></td>
<td class="bg"><p class="tab"><b class="calibre4">Henoch-Schönlein purpura</b> (IgA nephropathy + syst. vasculitis w/ IgA deposits, nl C3, ±↑ IgA)</p></td>
</tr>
</table>
<p class="h2a"><b class="calibre4">Oncology-related glomerulopathy</b> <span class="s">(<i class="calibre3">CJASN</i> 2016;11:1681)</span></p>
<p class="bl"><span class="sbl">•</span> Associations between malig (solid tumors &amp; heme) and/or their Rx (HSCT &amp; chemo-therapeutics) and GN, nephrotic syndrome, and thrombotic microangiopathies (TMA)</p>
<p class="bl"><span class="sbl">•</span> Most common associations: membranous (solid tumors, HSCT), MCD (Hodgkin’s, solid tumors), MPGN (CLL, MM), TMA (HSCT, VEGF, anti-EGFR, CNIs, TKIs, mTOR)</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Monoclonal glomerulopathy of renal significance:</b> Ig-mediated kidney disease by nonmalignant B or plasma cells. Workup: SPEP, sFLC, flow cytometry, IFE, BMBx.</p>
<p class="h2a"><b class="calibre4">Workup</b> <span class="s">(<i class="calibre3">JAMA</i> 2017;318:1276)</span></p>
<p class="bl"><span class="sbl">•</span> <i class="calibre3">Acute GN/RPGN</i> ± <i class="calibre3">lung hemorrhage is an emergency</i> → requires early Dx and Rx</p>
<p class="bl"><span class="sbl">•</span> UA + sediment (dysmorphic RBCs) ✔ ANCA, anti-GBM, C3/C4, SPEP, serum FLC</p>
<p class="bl"><span class="sbl">•</span> Depending on hx: ANA, anti-dsDNA/Sm, RF, Hep B&amp;C, HIV, ASLO, BCx, cryocrit, skin bx</p>
<p class="bl"><span class="sbl">•</span> Consider GN mimics: thrombotic microangiopathies (qv), myeloma, AIN, cholesterol emboli</p>
<p class="bl"><span class="sbl">•</span> Renal biopsy with immunofluorescence (IF) ± electron microscopy (EM)</p>
<p class="capf"><b class="calibre4">Figure 4-8</b> Approach to glomerulonephritis based on immunofluorescence pattern</p>
<p class="image"><img src="../images/00079.jpeg" alt="" class="calibre2"/></p>
<p class="h2a"><a id="page_4-18" class="calibre1"></a><b class="calibre4">Treatment</b> <span class="s">(<i class="calibre3">CJASN</i> 2017;12:1680)</span></p>
<p class="bl"><span class="sbl">•</span> If acute GN/RPGN suspected, give 500–1000 mg methylpred. IV qd × 3d <i class="calibre3">ASAP</i> while awaiting bx results. Consider plasmapheresis &amp; further Rx based on underlying disease.</p>
<p class="bl"><span class="sbl">•</span> SLE nephritis: induction w/ steroids + cyclophosphamide (CYC) or MMF <span class="s1r">(<i class="calibre3">CJASN</i> 2017;12:825)</span></p>
<p class="bl"><span class="sbl">•</span> ANCA ⊕ or anti-GBM: pulse steroids + CYC (or rituximab). Plasma exchange if severe AKI or pulm hemorrhage <span class="s">(<i class="calibre3">JASN</i> 2007;18:2180; <i class="calibre3">NEJM</i> 2010;363:221; <i class="calibre3">AJKD</i> 2011;57:566)</span>.</p>
<p class="bl"><span class="sbl">•</span> See “Vasculitis” for further disease-specific treatment details</p>
<p class="h">A<small class="calibre30">SYMPTOMATIC</small> G<small class="calibre30">LOMERULAR</small> H<small class="calibre30">EMATURIA</small></p>
<p class="h2a"><b class="calibre4">Definition and etiologies</b></p>
<p class="bl"><span class="sbl">•</span> Hematuria ± proteinuria of glomerular origin w/o renal insufficiency or systemic disease (nonglomerular more common; see “Hematuria”)</p>
<p class="bl"><span class="sbl">•</span> Ddx: any cause of GN (esp. IgA); also consider Alport’s (X-linked, deafness, renal failure), thin basement membrane nephropathy (autosomal dominant, benign; <i class="calibre3">JASN</i> 2013;23:364)</p>
<p class="h2a"><b class="calibre4">IgA nephropathy</b> <span class="s">(<i class="calibre3">NEJM</i> 2013;368:25; <i class="calibre3">CJASN</i> 2017;12:677)</span></p>
<p class="bl"><span class="sbl">•</span> Most common cause of GN; ♂ pred; peak incidence 20–30s; can also be post-infectious</p>
<p class="bl"><span class="sbl">•</span> Wide range of clinical presentations: asx hematuria (30–40%), gross hematuria ~1–3 d</p>
<p class="bl1">after URI (10–15%), chronic GN (10%), nephrotic syndrome (5%), RPGN (&lt;5%)</p>
<p class="bl"><span class="sbl">•</span> Though clinical presentation can be highly suggestive, definitive dx only w/ bx</p>
<p class="bl"><span class="sbl">•</span> Prognosis: ↑Cr, HTN, proteinuria a/w poor prog. <span class="s1r">(<i class="calibre3">AJKD</i> 2012;59:865)</span>. 20–40% ESRD w/in 20 y.</p>
<p class="bl"><span class="sbl">•</span> Rx: ACEI/ARB <span class="s">(<i class="calibre3">JASN</i> 1999;10:1772)</span>; steroids if persistent proteinuria (&gt; 1g/d; <i class="calibre3">NEJM</i> 2015;373: 2225); ± cytotoxic Rx for crescentic GN or HTN &amp; ↑ Cr <span class="s">(<i class="calibre3">JASN</i> 2012;23:1108)</span>; ? fish oil</p>
<p class="h">N<small class="calibre30">EPHROTIC</small> S<small class="calibre30">YNDROME</small></p>
<p class="h2a"><b class="calibre4">Definition</b> <span class="s">(<i class="calibre3">JASN</i> 2014;25:2393)</span></p>
<p class="bl"><span class="sbl">•</span> Podocyte injury (effacement) → loss of proteins (albumin, ATIII, Ig)</p>
<p class="bl"><span class="sbl">•</span> Clinically: proteinuria &gt;3.5 g/d, albumin &lt;3 g/dL, edema, ↑ chol., VTE (25%), infection</p>
<p class="h2a"><b class="calibre4">Primary glomerular diseases</b> <span class="s">(grouped by pathology)</span></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Focal segmental glomerulosclerosis</b> (40%; <i class="calibre3">CJASN</i> 2017;12:502): 1° (cytokine mediated); <i class="calibre3">adaptive</i> (hyperfiltration, sickle cell, obesity, anabolic steroids, OSA, ↑ protein, vesico-ureteral reflux); <i class="calibre3">genetic</i> <span class="s1r">(<i class="calibre3">ApoL1</i> mutation in AA <span class="s3">(<i class="calibre3">JASN</i> 2015;26:1443)</span></span>; <i class="calibre3">viral</i> (HIV most strongly associated); <i class="calibre3">meds/toxins</i> (IFN, bisphosphonates, NSAIDs, heroin)</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Membranous nephropathy</b> (30%; <i class="calibre3">Lancet</i> 2015;385:1983; <i class="calibre3">CJASN</i> 2017;12:938): 1° (Ab to PLA2R [70%] or THSD7A [5%]; <i class="calibre3">NEJM</i> 2014;371:2277); <i class="calibre3">infection</i> (HBV, HCV, HIV, syphilis); <i class="calibre3">autoimmune</i> (eg, SLE); <i class="calibre3">carcinomas</i>; <i class="calibre3">drugs</i> (NSAIDs, penicillamine)</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Minimal change disease</b> (20%, more common in children; <i class="calibre3">CJASN</i> 2017;12:332)</p>
<p class="bl1">allergies, NSAIDs, ampicillin, Hodgkin’s disease, SLE, DM, MG, celiac disease</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Membranoproliferative GN</b> (5%, <i class="calibre3">mixed</i> nephrotic/nephritic features; <i class="calibre3">CJASN</i> 2014;9:600)</p>
<p class="bl1">Immune complex mediated: infection (esp. HCV ± cryos, IE, HBV, “shunt” nephritis, other chronic infxns), SLE, cryos, Sjögren’s, lymphomas, dysproteinemia, idiopathic</p>
<p class="bl1">Complement mediated (rare); dense deposit disease (DDD), C3GN</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Fibrillary-immunotactoid glomerulopathy</b> (1%; <i class="calibre3">JASN</i> 2008;19:34)</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Mesangial proliferative GN</b> (? atypical forms of MCD/FSGS, 5%) IgM, C1q nephropathy</p>
<p class="h2a"><b class="calibre4">Systemic diseases with secondary glomerular involvement</b></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Diabetes mellitus</b> <span class="s1r">(<i class="calibre3">CJASN</i> 2017;12:2032)</span>: nodular glomerulosclerosis (Kimmelstiel-Wilson lesion); glomerular hyperfiltration → microalbuminuria → dipstick ⊕ → nephrotic range (10–15 y). Proliferative retinopathy seen in 90% of type 1 and 60% of type 2.</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Amyloidosis:</b> AL or light-chain amyloid or AA amyloid secondary to inflammation</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">SLE</b> <span class="s">(<i class="calibre3">CJASN</i> 2017;12:825)</span>: typically membranous nephropathy (WHO class V)</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Cryoglobulinemia</b> (AJKD 2016;67): a/w HCV, monoclonal gammopathy. Typically MPGN.</p>
<p class="h2a"><b class="calibre4">Workup</b> <span class="s">(<i class="calibre3">BMJ</i> 2008;336:1185)</span></p>
<p class="bl"><span class="sbl">•</span> U/A + sediment: usually benign; ± oval fat bodies (“Maltese crosses”; <i class="calibre3">NEJM</i> 2007;357:806)</p>
<p class="bl"><span class="sbl">•</span> Measure proteinuria: 24-h urine or spot urine protein/Cr ratio (not accurate in AKI), renal bx</p>
<p class="bl"><span class="sbl">•</span> 2° causes: ↑ Hb<sub class="calibre8">A1C</sub> + retinop. → DM; ✔ ANA, anti-dsDNA, tox screen, C3/C4, SPEP/light chains, fat pad bx, cryocrit, HBV/HCV, HIV, RPR, APLA2R Ab, age-approp. CA screen</p>
<p class="h2a"><b class="calibre4">Treatment</b> <span class="s">(<i class="calibre3">NEJM</i> 2013;368:10)</span></p>
<p class="bl"><span class="sbl">•</span> General: protein suppl.; diuretics for edema; treat hyperlipidemia, Na restriction (&lt;2 g/d)</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">ACEI</b> or <b class="calibre4">ARB:</b> ↓ proteinuria → slow nonimmunologic progression of renal disease</p>
<p class="bl"><span class="sbl">•</span> 1° glomerular: steroids ± cytotoxic therapy <span class="s">(<i class="calibre3">KI</i> 2012;2:139; <i class="calibre3">CJASN</i> 2014;9:1386)</span></p>
<p class="bl"><span class="sbl">•</span> Secondary causes: treat underlying disease</p>
<p class="bl"><span class="sbl">•</span> Watch for malnutrition (protein loss), consider anticoag if albumin &lt;2.5 in membranous <span class="s1r">(<i class="calibre3">KI</i> 2014;85:1412)</span>, infection (esp. encapsulated organisms b/c loss of Ig)</p>
<h2 class="ct"><a id="h59" class="calibre7"></a><a id="page_4-19" class="calibre7"></a><a href="part0002.html#rh66" class="calibre7">URINALYSIS</a></h2>
<table class="t-topbot1">
<colgroup class="calibre9">
<col class="calibre41"/>
<col class="calibre42"/>
</colgroup>
<tr class="calibre12">
<td class="bg1-b" colspan="2"><p class="tabheadc"><b class="calibre4">Urine Dipstick</b></p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Metric</b></p></td>
<td class="bg0-b"><p class="tab"><b class="calibre4">Significance and Uses</b></p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Specific</b></p>
<p class="tab"><b class="calibre4">gravity</b></p></td>
<td class="bg0-b"><p class="tab">Estimate U<sub class="calibre13">osm</sub>: each 0.001 above 1 ≈ 30 osm (SG 1.010 → U<sub class="calibre13">osm</sub> ≈ 300)</p>
<p class="tab">SG and U<sub class="calibre13">osm</sub> useful in evaluating AKI, dysnatremias, polyuria Heavy substances (glucose, contrast) ↑ SG more than U<sub class="calibre13">osm</sub></p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">pH</b></p></td>
<td class="bg0-b"><p class="tab">Range: 4.5–8.5; useful in evaluation of stones, RTAs, infection (urease UTI)</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Protein</b></p></td>
<td class="bg0-b"><p class="tab">Detects albuminuria (&gt;300 mg/d); see “Proteinuria”. False ⊖: dilute urine</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Blood</b></p></td>
<td class="bg0-b"><p class="tab">See “Hematuria”; ⊕ from RBCs, free Hgb, or free myoglobin (eg, rhabdo)</p>
<p class="tab">False ⊕: semen, dilute urine (→ osmotic cell lysis), ↑ pH, vaginal blood</p>
<p class="tab">False ⊖: vit C</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">WBC</b></p></td>
<td class="bg0-b"><p class="tab">Suggests inflammation (UTI, interstitial nephritis, GN)</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Ketones</b></p></td>
<td class="bg0-b"><p class="tab">Detects acetoacetate (ie, ketoacidosis) but <i class="calibre3">not</i> β-hydroxybutyrate</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Leuk est</b></p></td>
<td class="bg0-b"><p class="tab">Lysed PMNs. Sn 80% for UTI. FN: proteinuria, glycosuria FP: ↓ pH or SG</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Nitrite</b></p></td>
<td class="bg0-b"><p class="tab">Suggests presence of nitrate reductase ⊕ bacteria (most enteric GNRs)</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Bilirubin</b></p></td>
<td class="bg0-b"><p class="tab">↑ in biliary or hepatic disease</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-r"><p class="tab"><b class="calibre4">Glucose</b></p></td>
<td class="bg"><p class="tab">⊕ in hyperglycemia (&gt;180 mg/dL), pregnancy, Fanconi’s syndrome, SGLT2i</p></td>
</tr>
</table>
<table class="t-topbot1">
<colgroup class="calibre9">
<col class="calibre41"/>
<col class="calibre42"/>
</colgroup>
<tr class="calibre12">
<td class="bg1-b" colspan="2"><p class="tabheadc"><b class="calibre4">Urine Sediment (microscopic examination)</b> <span class="tfont1">(</span><span class="tfont1"><i class="calibre3">Am J Kidney Dis</i></span> <span class="tfont1">2008;5</span><span class="tfont1">1</span><span class="tfont1">:</span><span class="tfont1">1</span><span class="tfont1">052)</span></p></td>
</tr>
<tr class="calibre12">
<td class="bg0-b" colspan="2"><p class="tab"><b class="calibre4">Method:</b> Centrifuge fresh sample (prox. port if Foley) × 3–5 min at 1500–3000 rpm; pour off supernatant in one motion; resuspend pellet by agitating base of tube; pour suspension onto slide w/ coverslip; view under “high dry” power; phase contrast for RBC morphology</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Cells</b></p></td>
<td class="bg0-b"><p class="tab">RBCs: assess amount &amp; morphology (many dysmorphic → glomerular)</p>
<p class="tab">WBCs: PMNs (UTI) vs. eosinophils (AIN; may require special stain)</p>
<p class="tab">Epithelial cells: tubular (ATN), transitional (bladder or ureters), squamous</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Casts</b> <i class="calibre3">(see urinalysis photo inserts in appendix)</i></p></td>
<td class="bg0-b"><p class="tab"><i class="calibre3">Proteins molded in lumen of renal tubule</i> ± <i class="calibre3">entrapped cellular elements</i> RBC → GN</p>
<p class="tab">WBC → AIN, pyelonephritis, GN</p>
<p class="tab">Granular (“muddy brown”): degenerating cellular casts → ATN</p>
<p class="tab">Tubular cell → ATN</p>
<p class="tab">Hyaline: Tamm-Horsfall protein (nonspecific)</p>
<p class="tab">Waxy and broad → advanced chronic kidney disease</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-r"><p class="tab"><b class="calibre4">Crystals</b></p>
<p class="tab"><i class="calibre3">(see urinalysis photo inserts in appendix)</i></p></td>
<td class="bg"><p class="tab">Calcium oxalate monohydrate: spindle, oval, or dumbbell shaped</p>
<p class="tab">Calcium oxalate dihydrate: envelope shaped or octahedral</p>
<p class="tab">Uric acid: variable shape; polychromatic under polarized light</p>
<p class="tab">Cystine: hexagon shaped</p>
<p class="tab">Struvite: coffin-lid shaped; seen in chronic UTI with urea-splitting organisms</p>
<p class="tab">Drugs: sulfa, protease inhibitors: “shocks of wheat”; acyclovir: fine needles</p></td>
</tr>
</table>
<p class="h">P<small class="calibre30">ROTEINURIA</small></p>
<table class="t-topbot1">
<colgroup class="calibre9">
<col class="calibre29"/>
<col class="calibre27"/>
<col class="calibre17"/>
</colgroup>
<tr class="calibre12">
<td class="bg1-b" colspan="3"><p class="tabheadc"><b class="calibre4">Etiologies of Proteinuria</b></p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Category</b></p></td>
<td class="bg0-br"><p class="tab"><b class="calibre4">Description</b></p></td>
<td class="bg0-b"><p class="tab"><b class="calibre4">Etiologies</b></p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Glomerular</b></p>
<p class="tab">(can be &gt;3.5 g/d)</p></td>
<td class="bg0-br"><p class="tab">Disruption of filtration</p>
<p class="tab">barrier → lose albumin</p></td>
<td class="bg0-b"><p class="tab">Glomerulonephritis</p>
<p class="tab">Nephrotic syndrome</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Tubulointerstitial</b></p>
<p class="tab">(usually &lt;1–2 g/d)</p></td>
<td class="bg0-br"><p class="tab">↓ reabsorption of freely filtered proteins → lose globulins</p></td>
<td class="bg0-b"><p class="tab">ATN; AIN</p>
<p class="tab">Fanconi’s syndrome</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Overflow</b></p></td>
<td class="bg0-br"><p class="tab">↑ production of freely filtered proteins</p></td>
<td class="bg0-b"><p class="tab">Multiple myeloma</p>
<p class="tab">Myoglobinuria</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-r"><p class="tab"><b class="calibre4">Isolated</b></p></td>
<td class="bg0-r"><p class="tab">By def’n: asx, normal</p>
<p class="tab">renal fxn, sed, &amp; imaging, no</p>
<p class="tab">h/o renal disease</p></td>
<td class="bg"><p class="tab">Functional (fever, exercise, CHF) Orthostatic (only when upright) Idiopathic (transient or persistent)</p></td>
</tr>
</table>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Urine dipstick</b></p>
<p class="bl1">1+ ≈30 mg/dL, 2+ ≈100 mg/dL, 3+ ≈300 mg/dL, 4+ &gt;2 g/dL; interpretation depends on SG; eg, 3+ in very concentrated urine might not indicate heavy proteinuria</p>
<p class="bl1">Insensitive for microalbuminuria and myeloma light chains (Bence-Jones protein)</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Spot urine:</b> protein (mg/dL)/creatinine (mg/dL) ≈ g/d of proteinuria <span class="s1r">(<i class="calibre3">NEJM</i> 1983;309:1543)</span></p>
<p class="bl1">unlike urine dipstick, will accurately measure myeloma light chains</p>
<p class="bl1">reliable surrogate for 24-hr urine, esp. 1<sup class="calibre15">st</sup> morning void <span class="s1r">(<i class="calibre3">JASN</i> 2009;20:436)</span>; inaccurate if AKI</p>
<p class="bl1">depends on Cr production, ∴ underestimates if muscular, overestimates if cachectic</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Moderate albuminuria</b> (30–300 mg/d <i class="calibre3">or</i> mg/L <i class="calibre3">or</i> mg/g Cr): early sign of glomerular vascular disease; marker for ↑ risk of CV adverse outcomes <span class="s">(<i class="calibre3">KI</i> 2013;3:19)</span></p>
<p class="bl"><a id="page_4-20" class="calibre1"></a><span class="sbl">•</span> Orthostatic proteinuria: typically in adolescents; ~90% of young ♂ with isolated proteinuria have orthostatic proteinuria; typically resolves spontaneously</p>
<p class="h">H<small class="calibre30">EMATURIA</small></p>
<table class="t-topbot1">
<colgroup class="calibre9">
<col class="calibre17"/>
<col class="calibre24"/>
</colgroup>
<tr class="calibre12">
<td class="bg1-b" colspan="2"><p class="tabheadc"><b class="calibre4">Etiologies of Hematuria</b></p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Extrarenal</b> (far more common)</p></td>
<td class="bg0-b"><p class="tab"><b class="calibre4">Intrarenal</b></p></td>
</tr>
<tr class="calibre12">
<td class="bg0-r"><p class="tab">Nephrolithiasis</p>
<p class="tab">Neoplasm: transitional cell, prostate</p>
<p class="tab">Infxn: cystitis, urethritis, prostatitis</p>
<p class="tab">Foley trauma</p>
<p class="tab">BPH</p>
<p class="tab">Schistosoma haematobium</p></td>
<td class="bg"><p class="tab">Nephrolithiasis or crystalluria</p>
<p class="tab">Neoplasm</p>
<p class="tab">Trauma/exercise (? extrarenal component)</p>
<p class="tabh">Vascular: renal infarcts, renal vein thromb., sickle cell, ruptured hemangioma</p>
<p class="tab">Glomerular: IgA, thin BM, others</p>
<p class="tab">PKD <span class="tfont1">(</span><span class="tfont1"><i class="calibre3">NEJM</i></span> <span class="tfont1">2008;359:</span><span class="tfont1">1</span><span class="tfont1">477)</span></p></td>
</tr>
</table>
<p class="bl"><span class="sbl">•</span> Wide, overlapping ages for various etiologies, but general guide for common causes:</p>
<p class="bl1">&lt;20 y: GN, UTI, congenital; 20–60 y: UTI, nephrolithiasis, cancer</p>
<p class="bl1">&gt;60 y ♂: prostatitis, cancer, UTI; &gt;60 y ♀: UTI, cancer</p>
<p class="h2a"><b class="calibre4">Workup</b> <span class="s">(<i class="calibre3">JAMA</i> 2017;177:800)</span></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Urine dipstick:</b> ⊕ if ≥3 RBCs; ⊕ dipstick and ⊖ sediment → myo- or hemoglobinuria</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Urine sediment:</b> dysmorphic RBCs or RBC casts → GN → consider renal bx</p>
<p class="bl"><span class="sbl">•</span> Dx: <i class="calibre3">CT urography</i>: r/o nephrolithiasis &amp; neoplasia (Se 96%, Sp 98%); <i class="calibre3">urine cytology</i> (Se 70%, Sp 95%); <i class="calibre3">cystoscopy</i>: r/o bladder neoplasia, esp if Pt ≥35 y</p>
<p class="bl"><span class="sbl">•</span> Rx: if obstruction: bladder irrigation and 3-way Foley on CBI</p>
<h2 class="ct"><a id="h60" class="calibre7"></a><a href="part0002.html#rh67" class="calibre7">NEPHROLITHIASIS</a></h2>
<p class="h2a"><b class="calibre4">Types of stones and risk factors</b> <span class="s">(<i class="calibre3">Nat Rev</i> 2016;2:16008)</span></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Calcium</b> (Ca oxalate &gt; Ca phosphate): <b class="calibre4">70–90% of kidney stones</b> <span class="s">(<i class="calibre3">NEJM</i> 2010;363:954)</span></p>
<p class="bl1">Urine findings: ↑ Ca, ↑ oxalate (Ca-ox only), ↑ pH (Ca-phos only), ↓ citrate, ↓ volume</p>
<p class="bl1">2° hypercalciuria: 1° hyperparathyroidism, distal RTA, sarcoid, Li use</p>
<p class="bl1">2° hyperoxaluria: Crohn’s, ileal disease w/ intact colon, gastric bypass, pancreatic insuffic.</p>
<p class="bl1">Diet: ↑ animal protein, ↑ sucrose, ↑ Na, ↓ K, ↓ fluid, ↓ fruits/vegetables, ↑ vit. C, ↓ Ca</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Uric acid:</b> 5–10% of kidney stones, radiolucent on plain film</p>
<p class="bl1">Urine findings: ↑ uric acid, ↓ pH (eg, from chronic diarrhea)</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Magnesium ammonium phosphate</b> (“struvite” or “triple phosphate”)</p>
<p class="bl1">Chronic upper UTI w/ urea-splitting organisms (eg, <i class="calibre3">Proteus, Klebs</i>) → ↑ urine NH<sub class="calibre8">3</sub>, pH &gt;7</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Cystine:</b> inherited defects of tubular amino acid reabsorption</p>
<p class="h2a"><b class="calibre4">Clinical manifestations</b></p>
<p class="bl"><span class="sbl">•</span> Hematuria (absence does not exclude diagnosis), flank pain, N/V, dysuria, frequency</p>
<p class="bl"><span class="sbl">•</span> Ureteral obstruction (stones &gt;5 mm unlikely to pass spont.) → AKI if solitary kidney</p>
<p class="bl"><span class="sbl">•</span> UTI: ↑ risk of infection proximal to stone; urinalysis of distal urine may be normal</p>
<p class="h2a"><b class="calibre4">Workup</b> <span class="s">(<i class="calibre3">Urology</i> 2014;84:533)</span></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Non-contrast CT</b> 97% Se, 96% Sp (ureteral dilation w/o stone suggests recent passage); U/S (Se 57%, Sp 98%) may serve as initial test in stable patient <span class="s">(<i class="calibre3">NEJM</i> 2014;371:1100)</span></p>
<p class="bl"><span class="sbl">•</span> Strain urine for stone to analyze; U/A &amp; UCx; electrolytes, BUN/Cr, Ca, PO<sub class="calibre8">4</sub>, PTH</p>
<p class="bl"><span class="sbl">•</span> 24-h urine × 2 (&gt;6 wk after acute setting) for Ca, PO<sub class="calibre8">4</sub>, oxalate, citrate, Na, Cr, pH, K, vol.</p>
<p class="h2a"><b class="calibre4">Acute treatment</b> <span class="s">(<i class="calibre3">CJASN</i> 2016;11:1305)</span></p>
<p class="bl"><span class="sbl">•</span> Analgesia (narcotics ± NSAIDs; combination superior, <i class="calibre3">Ann Emerg Med</i> 2006;48:173), ensure adequate fluid repletion, antibiotics if UTI</p>
<p class="bl"><span class="sbl">•</span> α-blocker &gt; CCB to pass stone if ≤10 mm (Cochrane;2014:CD008509, <i class="calibre3">Lancet</i> 2006;368:1171)</p>
<p class="bl"><span class="sbl">•</span> Indications for <b class="calibre4">immediate urologic eval and</b>/<b class="calibre4">or hosp:</b> obstruction (esp. solitary or transplant kidney), urosepsis, intractable pain or vomiting, significant AKI</p>
<p class="bl"><span class="sbl">•</span> Urologic Rx: lithotripsy <span class="s1r">(<i class="calibre3">NEJM</i> 2012:367:50)</span>, ureteroscopic removal, lap/perc nephrolithotomy</p>
<p class="h2a"><b class="calibre4">Chronic treatment</b> <span class="s">(<i class="calibre3">CJASN</i> 2016;11:1305 &amp; 2017;12:1699)</span></p>
<p class="bl"><span class="sbl">•</span> Increase fluid intake (&gt;2 L/d) for goal UOP 2 L/d <span class="s">(<i class="calibre3">J Nephrol</i> 2016;29:211)</span></p>
<p class="bl"><span class="sbl">•</span> Calcium stones: 24-h urine identifies <b class="calibre4">specific urinary risk factors to treat</b></p>
<p class="bl1">Diet: ↓ Na and meat <span class="s1r">(<i class="calibre3">NEJM</i> 2002;346:77)</span>, ↓ oxalate foods &amp; sucrose/fructose</p>
<p class="bl1">Meds: thiazides (↓ urine Ca), K-citrate if low urine citrate, allopurinol if high urine uric acid</p>
<p class="bl1">Avoid low dietary Ca as ↑ oxalate absorp <span class="s1r">(<i class="calibre3">NEJM</i> 2002;346:77)</span>, unclear role of Ca suppl.</p>
<p class="bl"><span class="sbl">•</span> Uric acid: fluid intake, urine alkalinization (K-citrate) to pH 6.5–7, allopurinol</p>
<p class="bl"><span class="sbl">•</span> Magnesium ammonium phosphate (struvite): antibiotics for UTI; urologic intervention; acetohydroxamic acid; urease inhibitor reserved for experienced clinician, poorly tolerated</p>
<p class="bl"><span class="sbl">•</span> Cystine: fluid, urine alkaliniz (K-citrate) to 7–8, <small class="calibre40">D</small>-penicillamine, tiopronin <span class="s1r">(<i class="calibre3">KI</i> 2006;69:1041)</span></p>


  </div>

  
  <div class="calibreToc">
    <h2><a href="../../k34gmbu8.html">Table of contents
</a></h2>
    <div>
  <ul>
    <li>
      <a href="part0000.html#0-74951b69f9a94472af57c47504abb1f1">Title Page</a>
    </li>
    <li>
      <a href="part0001.html#UGI0-74951b69f9a94472af57c47504abb1f1">Copyright Page</a>
    </li>
    <li>
      <a href="part0002.html#1T140-74951b69f9a94472af57c47504abb1f1">Contents</a>
    </li>
    <li>
      <a href="part0003.html#2RHM0-74951b69f9a94472af57c47504abb1f1">Contributing Authors</a>
    </li>
    <li>
      <a href="part0004.html#3Q280-74951b69f9a94472af57c47504abb1f1">Foreword</a>
    </li>
    <li>
      <a href="part0005.html#4OIQ0-74951b69f9a94472af57c47504abb1f1">Preface</a>
    </li>
    <li>
      <a href="part0006.html#5N3C0-74951b69f9a94472af57c47504abb1f1">Cardiology</a>
      <ul>
        <li>
          <a href="part0006.html#h1">Electrocardiography</a>
        </li>
        <li>
          <a href="part0006.html#h2">Chest Pain</a>
        </li>
        <li>
          <a href="part0006.html#h3">Noninvasive Evaluation of CAD</a>
        </li>
        <li>
          <a href="part0006.html#h4">Coronary Angiography and Revascularization</a>
        </li>
        <li>
          <a href="part0006.html#h5">Acute Coronary Syndromes</a>
        </li>
        <li>
          <a href="part0006.html#h6">PA Catheter and Tailored Therapy</a>
        </li>
        <li>
          <a href="part0006.html#h7">Heart Failure</a>
        </li>
        <li>
          <a href="part0006.html#h8">Cardiomyopathies</a>
        </li>
        <li>
          <a href="part0006.html#h9">Valvular Heart Disease</a>
        </li>
        <li>
          <a href="part0006.html#h10">Pericardial Disease</a>
        </li>
        <li>
          <a href="part0006.html#h11">Hypertension</a>
        </li>
        <li>
          <a href="part0006.html#h12">Aortic Aneurysms</a>
        </li>
        <li>
          <a href="part0006.html#h13">Acute Aortic Syndromes</a>
        </li>
        <li>
          <a href="part0006.html#h14">Arrhythmias</a>
        </li>
        <li>
          <a href="part0006.html#h15">Atrial Fibrillation</a>
        </li>
        <li>
          <a href="part0006.html#h16">Syncope</a>
        </li>
        <li>
          <a href="part0006.html#h17">Cardiac Rhythm Management Devices</a>
        </li>
        <li>
          <a href="part0006.html#h18">Cardiac Risk Assessment for Noncardiac Surgery</a>
        </li>
        <li>
          <a href="part0006.html#h19">Peripheral Artery Disease</a>
        </li>
      </ul>
    </li>
    <li>
      <a href="part0007.html#6LJU0-74951b69f9a94472af57c47504abb1f1">Pulmonary</a>
      <ul>
        <li>
          <a href="part0007.html#h20">Dyspnea</a>
        </li>
        <li>
          <a href="part0007.html#h21">Pulmonary Function Tests</a>
        </li>
        <li>
          <a href="part0007.html#h22">Asthma</a>
        </li>
        <li>
          <a href="part0007.html#h23">Anaphylaxis</a>
        </li>
        <li>
          <a href="part0007.html#h24">Chronic Obstructive Pulmonary Disease</a>
        </li>
        <li>
          <a href="part0007.html#h25">Solitary Pulmonary Nodule</a>
        </li>
        <li>
          <a href="part0007.html#h26">Hemoptysis</a>
        </li>
        <li>
          <a href="part0007.html#h27">Bronchiectasis</a>
        </li>
        <li>
          <a href="part0007.html#h28">Cystic Fibrosis</a>
        </li>
        <li>
          <a href="part0007.html#h29">Interstitial Lung Disease</a>
        </li>
        <li>
          <a href="part0007.html#h30">Pleural Effusion</a>
        </li>
        <li>
          <a href="part0007.html#h31">Venous Thromboembolism</a>
        </li>
        <li>
          <a href="part0007.html#h32">Pulmonary Hypertension</a>
        </li>
        <li>
          <a href="part0007.html#h33">Respiratory Failure</a>
        </li>
        <li>
          <a href="part0007.html#h34">Mechanical Ventilation</a>
        </li>
        <li>
          <a href="part0007.html#h35">Acute Respiratory Distress Syndrome</a>
        </li>
        <li>
          <a href="part0007.html#h36">Sepsis and Shock</a>
        </li>
        <li>
          <a href="part0007.html#h37">Toxicology</a>
        </li>
        <li>
          <a href="part0007.html#h38">Lung Transplant</a>
        </li>
      </ul>
    </li>
    <li>
      <a href="part0008.html#7K4G0-74951b69f9a94472af57c47504abb1f1">Gastroenterology</a>
      <ul>
        <li>
          <a href="part0008.html#h39">Esophageal and Gastric Disorders</a>
        </li>
        <li>
          <a href="part0008.html#h40">Gastrointestinal Bleeding</a>
        </li>
        <li>
          <a href="part0008.html#h41">Diarrhea</a>
        </li>
        <li>
          <a href="part0008.html#h42">Dysmotility &amp; Nutrition</a>
        </li>
        <li>
          <a href="part0008.html#h43">Disorders of the Colon</a>
        </li>
        <li>
          <a href="part0008.html#h44">Inflammatory Bowel Disease</a>
        </li>
        <li>
          <a href="part0008.html#h45">Intestinal Ischemia</a>
        </li>
        <li>
          <a href="part0008.html#h46">Pancreatitis</a>
        </li>
        <li>
          <a href="part0008.html#h47">Abnormal Liver Tests</a>
        </li>
        <li>
          <a href="part0008.html#h48">Hepatitis</a>
        </li>
        <li>
          <a href="part0008.html#h49">Acute Liver Failure</a>
        </li>
        <li>
          <a href="part0008.html#h50">Cirrhosis</a>
        </li>
        <li>
          <a href="part0008.html#h51">Hepatic Vascular Disease</a>
        </li>
        <li>
          <a href="part0008.html#h52">Ascites</a>
        </li>
        <li>
          <a href="part0008.html#h53">Biliary Tract Disease</a>
        </li>
      </ul>
    </li>
    <li>
      <a href="part0009.html#8IL20-74951b69f9a94472af57c47504abb1f1">Nephrology</a>
      <ul>
        <li>
          <a href="part0009.html#h54">Acid-Base Disturbances</a>
        </li>
        <li>
          <a href="part0009.html#h55">Sodium and Water Homeostasis</a>
        </li>
        <li>
          <a href="part0009.html#h56">Potassium Homeostasis</a>
        </li>
        <li>
          <a href="part0009.html#h57">Renal Failure</a>
        </li>
        <li>
          <a href="part0009.html#h58">Glomerular Disease</a>
        </li>
        <li>
          <a href="part0009.html#h59">Urinalysis</a>
        </li>
        <li>
          <a href="part0009.html#h60">Nephrolithiasis</a>
        </li>
      </ul>
    </li>
    <li>
      <a href="part0010.html#9H5K0-74951b69f9a94472af57c47504abb1f1">Hematology-Oncology</a>
      <ul>
        <li>
          <a href="part0010.html#h61">Anemia</a>
        </li>
        <li>
          <a href="part0010.html#h62">Disorders of Hemostasis</a>
        </li>
        <li>
          <a href="part0010.html#h63">Platelet Disorders</a>
        </li>
        <li>
          <a href="part0010.html#h64">Coagulopathies</a>
        </li>
        <li>
          <a href="part0010.html#h65">Hypercoagulable States</a>
        </li>
        <li>
          <a href="part0010.html#h66">Disorders of Leukocytes</a>
        </li>
        <li>
          <a href="part0010.html#h67">Transfusion Therapy</a>
        </li>
        <li>
          <a href="part0010.html#h68">Myelodysplastic Syndromes</a>
        </li>
        <li>
          <a href="part0010.html#h69">Myeloproliferative Neoplasms</a>
        </li>
        <li>
          <a href="part0010.html#h70">Leukemia</a>
        </li>
        <li>
          <a href="part0010.html#h71">Lymphoma</a>
        </li>
        <li>
          <a href="part0010.html#h72">Plasma Cell Dyscrasias</a>
        </li>
        <li>
          <a href="part0010.html#h73">Hematopoietic Stem Cell Transplantation</a>
        </li>
        <li>
          <a href="part0010.html#h74">Lung Cancer</a>
        </li>
        <li>
          <a href="part0010.html#h75">Breast Cancer</a>
        </li>
        <li>
          <a href="part0010.html#h76">Prostate Cancer</a>
        </li>
        <li>
          <a href="part0010.html#h77">Colorectal Cancer</a>
        </li>
        <li>
          <a href="part0010.html#h78">Pancreatic Tumors</a>
        </li>
        <li>
          <a href="part0010.html#h79">Hepatocellular Carcinoma (HCC)</a>
        </li>
        <li>
          <a href="part0010.html#h80">Oncologic Emergencies</a>
        </li>
        <li>
          <a href="part0010.html#h81">Chemotherapy &amp; Immunotherapy Side Effects</a>
        </li>
      </ul>
    </li>
    <li>
      <a href="part0011.html#AFM60-74951b69f9a94472af57c47504abb1f1">Infectious Diseases</a>
      <ul>
        <li>
          <a href="part0011.html#h82">Pneumonia</a>
        </li>
        <li>
          <a href="part0011.html#h83">Fungal Infections</a>
        </li>
        <li>
          <a href="part0011.html#h84">Infections in Immunosuppressed Hosts</a>
        </li>
        <li>
          <a href="part0011.html#h85">Urinary Tract Infections</a>
        </li>
        <li>
          <a href="part0011.html#h86">Soft Tissue and Bone Infections</a>
        </li>
        <li>
          <a href="part0011.html#h87">Infections of the Nervous System</a>
        </li>
        <li>
          <a href="part0011.html#h88">Bacteremia &amp; Endocarditis</a>
        </li>
        <li>
          <a href="part0011.html#h89">Tuberculosis</a>
        </li>
        <li>
          <a href="part0011.html#h90">HIV/AIDS</a>
        </li>
        <li>
          <a href="part0011.html#h91">Tick-Borne Diseases</a>
        </li>
        <li>
          <a href="part0011.html#h92">Fever Syndromes</a>
        </li>
      </ul>
    </li>
    <li>
      <a href="part0012.html#BE6O0-74951b69f9a94472af57c47504abb1f1">Endocrinology</a>
      <ul>
        <li>
          <a href="part0012.html#h93">Pituitary Disorders</a>
        </li>
        <li>
          <a href="part0012.html#h94">Thyroid Disorders</a>
        </li>
        <li>
          <a href="part0012.html#h95">Adrenal Disorders</a>
        </li>
        <li>
          <a href="part0012.html#h96">Calcium Disorders</a>
        </li>
        <li>
          <a href="part0012.html#h97">Diabetes Mellitus</a>
        </li>
        <li>
          <a href="part0012.html#h98">Lipid Disorders</a>
        </li>
      </ul>
    </li>
    <li>
      <a href="part0013.html#CCNA0-74951b69f9a94472af57c47504abb1f1">Rheumatology</a>
      <ul>
        <li>
          <a href="part0013.html#h99">Approach to Rheumatic Disease</a>
        </li>
        <li>
          <a href="part0013.html#h100">Rheumatoid Arthritis</a>
        </li>
        <li>
          <a href="part0013.html#h101">Adult-Onset Still’s Disease &amp; Relapsing Polychondritis</a>
        </li>
        <li>
          <a href="part0013.html#h102">Crystal Deposition Arthritides</a>
        </li>
        <li>
          <a href="part0013.html#h103">Seronegative Spondyloarthritis</a>
        </li>
        <li>
          <a href="part0013.html#h104">Infectious Arthritis &amp; Bursitis</a>
        </li>
        <li>
          <a href="part0013.html#h105">Connective Tissue Diseases</a>
        </li>
        <li>
          <a href="part0013.html#h106">Systemic Lupus Erythematosus</a>
        </li>
        <li>
          <a href="part0013.html#h107">Vasculitis</a>
        </li>
        <li>
          <a href="part0013.html#h108">IgG4-Related Disease</a>
        </li>
        <li>
          <a href="part0013.html#h109">Cryoglobulinemia</a>
        </li>
        <li>
          <a href="part0013.html#h110">Amyloidosis</a>
        </li>
      </ul>
    </li>
    <li>
      <a href="part0014.html#DB7S0-74951b69f9a94472af57c47504abb1f1">Neurology</a>
      <ul>
        <li>
          <a href="part0014.html#h111">Change in Mental Status</a>
        </li>
        <li>
          <a href="part0014.html#h112">Seizures</a>
        </li>
        <li>
          <a href="part0014.html#h113">Alcohol Withdrawal</a>
        </li>
        <li>
          <a href="part0014.html#h114">Dizziness</a>
        </li>
        <li>
          <a href="part0014.html#h115">Stroke</a>
        </li>
        <li>
          <a href="part0014.html#h116">Weakness &amp; Neuromuscular Dysfunction</a>
        </li>
        <li>
          <a href="part0014.html#h117">Headache</a>
        </li>
        <li>
          <a href="part0014.html#h118">Back and Spinal Cord Disease</a>
        </li>
      </ul>
    </li>
    <li>
      <a href="part0015.html#E9OE0-74951b69f9a94472af57c47504abb1f1">Consults</a>
      <ul>
        <li>
          <a href="part0015.html#h119">Surgical Issues</a>
        </li>
        <li>
          <a href="part0015.html#h120">Ob/Gyn Issues</a>
        </li>
        <li>
          <a href="part0015.html#h121">Ophthalmic Issues</a>
        </li>
      </ul>
    </li>
    <li>
      <a href="part0016.html#F8900-74951b69f9a94472af57c47504abb1f1">Appendix</a>
      <ul>
        <li>
          <a href="part0016.html#h122">ICU Medications &amp; Treatment of Hypotension/Shock</a>
        </li>
        <li>
          <a href="part0016.html#h123">Antibiotics</a>
        </li>
        <li>
          <a href="part0016.html#h124">Formulae and Quick Reference</a>
        </li>
      </ul>
    </li>
    <li>
      <a href="part0017.html#G6PI0-74951b69f9a94472af57c47504abb1f1">Abbreviations</a>
    </li>
    <li>
      <a href="part0018.html#H5A40-74951b69f9a94472af57c47504abb1f1">Index</a>
    </li>
    <li>
      <a href="part0019.html#I3QM0-74951b69f9a94472af57c47504abb1f1">Photo Inserts</a>
      <ul>
        <li>
          <a href="part0019.html#h125">Radiology</a>
        </li>
        <li>
          <a href="part0019.html#h126">Echocardiography &amp; Coronary Angiography</a>
        </li>
        <li>
          <a href="part0019.html#h127">Peripheral Blood Smears &amp; Leukemias</a>
        </li>
        <li>
          <a href="part0019.html#h128">Urinalysis</a>
        </li>
      </ul>
    </li>
    <li>
      <a href="part0022.html#KVCC0-74951b69f9a94472af57c47504abb1f1">ACLS</a>
    </li>
  </ul>
</div>


  </div>
  

  <div class="calibreEbNav">
    
      <a href="part0008.html" class="calibreAPrev">previous page
</a>
    

    <a href="../../k34gmbu8.html" class="calibreAHome">start
</a>

    
      <a href="part0010.html" class="calibreANext">next page
</a>
    
  </div>

</div>

</body>
</html>
